<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Healthcare Law - KIELTYKA GLADKOWSKI LEGAL | CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</title>
	<atom:link href="https://www.kg-legal.eu/info/tag/healthcare-law/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.kg-legal.eu/info/tag/healthcare-law/</link>
	<description>KIELTYKA GLADKOWSKI LEGAL &#124; CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</description>
	<lastBuildDate>Wed, 04 Nov 2026 10:55:29 +0000</lastBuildDate>
	<language>en-GB</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	
	<item>
		<title>Artificial Intelligence in Healthcare: the Risks Behind the Promise</title>
		<link>https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/artificial-intelligence-in-healthcare-the-risks-behind-the-promise/</link>
					<comments>https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/artificial-intelligence-in-healthcare-the-risks-behind-the-promise/#respond</comments>
		
		<dc:creator><![CDATA[jakub]]></dc:creator>
		<pubDate>Wed, 04 Nov 2026 10:55:29 +0000</pubDate>
				<category><![CDATA[PHARMACEUTICAL, HEALTHCARE & LIFE SCIENCES LAW]]></category>
		<category><![CDATA[AI Ethics]]></category>
		<category><![CDATA[AI in healthcare]]></category>
		<category><![CDATA[AI Regulation]]></category>
		<category><![CDATA[AI Transparency]]></category>
		<category><![CDATA[Algorithmic Accountability]]></category>
		<category><![CDATA[algorithmic bias]]></category>
		<category><![CDATA[Algorithmic Errors]]></category>
		<category><![CDATA[Artificial intelligence]]></category>
		<category><![CDATA[Clinical Decision Support]]></category>
		<category><![CDATA[Clinical Validation]]></category>
		<category><![CDATA[Clinician Training]]></category>
		<category><![CDATA[Data Quality]]></category>
		<category><![CDATA[data security]]></category>
		<category><![CDATA[Dataset Shift]]></category>
		<category><![CDATA[digital health]]></category>
		<category><![CDATA[EU AI Act]]></category>
		<category><![CDATA[European Health Data Space]]></category>
		<category><![CDATA[Explainable AI]]></category>
		<category><![CDATA[Health Data Protection]]></category>
		<category><![CDATA[Health Equity]]></category>
		<category><![CDATA[healthcare cybersecurity]]></category>
		<category><![CDATA[Healthcare Interoperability]]></category>
		<category><![CDATA[Healthcare Law]]></category>
		<category><![CDATA[healthcare technology]]></category>
		<category><![CDATA[Human Oversight]]></category>
		<category><![CDATA[informed consent]]></category>
		<category><![CDATA[KG Legal]]></category>
		<category><![CDATA[kglegal]]></category>
		<category><![CDATA[kiełtyka gładkowski]]></category>
		<category><![CDATA[Machine Learning]]></category>
		<category><![CDATA[Medical AI]]></category>
		<category><![CDATA[Medical Devices Regulation]]></category>
		<category><![CDATA[Medical Diagnostics]]></category>
		<category><![CDATA[Medical Imaging]]></category>
		<category><![CDATA[Medical Liability]]></category>
		<category><![CDATA[patient privacy]]></category>
		<category><![CDATA[patient safety]]></category>
		<category><![CDATA[Polish law]]></category>
		<category><![CDATA[Responsible AI]]></category>
		<guid isPermaLink="false">https://www.kg-legal.eu/?p=8974</guid>

					<description><![CDATA[<p>Publication date: November 04, 2026 Errors, bias, opacity, data security and the accountability gap &#8211; what patients, clinicians and regulators need to watch Artificial intelligence is already reading scans, ranking medical literature, predicting kidney failure and managing hospital beds. Its potential to make medicine faster, more precise and more personalised seems almost limitless. Yet the [&#8230;]</p>
<p>Artykuł <a href="https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/artificial-intelligence-in-healthcare-the-risks-behind-the-promise/">Artificial Intelligence in Healthcare: the Risks Behind the Promise</a> pochodzi z serwisu <a href="https://www.kg-legal.eu">KIELTYKA GLADKOWSKI LEGAL | CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p><strong><mark style="background-color:rgba(0, 0, 0, 0)" class="has-inline-color has-vivid-cyan-blue-color">Publication date: November 04, 2026</mark></strong></p>



<p><em>Errors, bias, opacity, data security and the accountability gap &#8211; what patients, clinicians and regulators need to watch</em></p>



<p><strong>Artificial intelligence is already reading scans, ranking medical literature, predicting kidney failure and managing hospital beds. Its potential to make medicine faster, more precise and more personalised seems almost limitless. Yet the same technology brings a distinct set of risks: algorithms that fail silently, tools used without adequate training, models that reproduce existing inequalities, decisions that no one can explain, patient data that is exposed or re-used, and a legal framework that still struggles to say who is responsible when something goes wrong. This article maps those risks and outlines what is needed to manage them.</strong></p>



<span id="more-8974"></span>



<h1 class="wp-block-heading"><strong>Where AI is already used in medicine</strong></h1>



<p>Interest in the use of artificial intelligence (AI) in healthcare has grown rapidly in recent years. Medical science is constantly expanding its horizons and generating ever larger and more diverse volumes of information. AI plays a key role in this evolution, becoming increasingly integrated into medical practice and offering healthcare systems in Europe a way to respond to the pressures they face.</p>



<p>Today, AI is used in medicine mainly for the quantification of medical images, the automated analysis of genetic data, disease prediction, medical robotics, telemedicine and virtual assistants. The COVID-19 pandemic significantly accelerated the development and deployment of AI applications in medical and clinical settings, as AI technologies became a central element of the response to the global health crisis.</p>



<p>AI is now applied across radiology, ophthalmology, dermatology and pathology. In cardiology, it is transforming clinical practice through the automated processing of cardiac data: machine learning models improve the diagnosis of heart disease by analysing complex imaging such as echocardiograms and electrocardiograms, help assess cardiac risk and predict treatment outcomes, contributing to better patient care and a lower burden of cardiovascular disease. Although AI is less widespread in nephrology, progress is being made in the diagnosis of kidney disease. Machine learning models can analyse ultrasound images of the kidneys and histopathological findings to identify pathological changes and assess disease severity, and AI can predict acute kidney injury from clinical and laboratory data, enabling faster diagnosis and treatment of patients in potentially life-threatening conditions. In biomedical research, AI is used primarily to analyse scientific publications: platforms such as PubMed use machine learning algorithms to rank search results, and newer tools such as the Best Match algorithm improve access to clinical knowledge.</p>



<p>In surgery, decisions sometimes have to be made quickly and without complete certainty about the diagnosis or the patient&#8217;s likely response to treatment. A lack of data or insufficient evidence can push clinicians towards mental shortcuts and intuition, which may lead to errors and bias. Traditional decision-support tools often fail to account for these limitations. AI-based models show promising efficacy in predicting risk for individual patients, which may prove particularly valuable in cardiovascular medicine.</p>



<p>AI is not confined to clinical medicine; it is also used in healthcare administration. One argument for deploying AI in administrative work is that errors there are usually less critical than errors in the clinical setting. AI-based applications can play a key role in organising patient flow, for example by managing bed availability, which is an important factor in surgery cancellations. Another administrative area is clinical coding &#8211; the process of extracting information from clinical records and classifying it under systems such as the International Classification of Diseases (ICD) or diagnosis-related groups (DRGs). Coding accuracy is crucial for cost recovery, management and analytics. Although computer-assisted coding has existed for some time, AI can significantly increase the accuracy and transparency of the process.</p>



<p>Despite these benefits, concerns about the possible negative effects of AI in medicine have grown in recent years. This fast-developing field raises considerable concern among healthcare professionals, patients and the public regarding clinical safety, equal access, privacy and security, appropriate use, liability and regulation. These risks can lead not only to harm to patients and citizens but also to a loss of public trust in AI algorithms and in doctors themselves.</p>



<h2 class="wp-block-heading"><strong>When the algorithm gets it wrong: AI errors</strong></h2>



<p>One of the main challenges is the unavoidable possibility of algorithmic error, which can have serious consequences for patients. Errors may have different causes and manifest themselves at different stages of the diagnostic and therapeutic process. A misdiagnosis may result in unnecessary treatment or in a serious illness being overlooked. In emergency departments, inappropriate interventions may follow from imprecise diagnoses or incorrect triage prioritisation.</p>



<p>An important aspect is the way data is collected and used in the machine learning process. Noise in input data, whether caused by technological imperfections or human factors, can significantly reduce the predictive accuracy of AI algorithms. Ultrasound imaging, for example, although widely used in clinical practice, is prone to operator-dependent scanning errors that can lead to incorrect results.</p>



<p>Dataset shift &#8211; a change in the statistical distribution of the data on which an algorithm was trained &#8211; is another major problem. It may result from differences between populations, from differing data acquisition protocols across medical facilities or from the use of different diagnostic technologies. A model trained on data from one type of scanner, for instance, may lose accuracy when applied to data from another.</p>



<p>AI algorithms may also have difficulty adapting to unexpected changes in the clinical environment. What a radiologist would immediately recognise as an artefact on an X-ray may be interpreted by an AI system as a pathological change, leading to false-positive results and unnecessary further investigation or intervention.</p>



<p>To minimise these risks, standardised methods for the assessment and approval of AI solutions by the competent regulatory authorities are essential. In keeping with the principles of ethics and safety, AI algorithms should be designed as tools that support doctors rather than replace them. It is also important that AI solutions remain dynamic, with the ability to keep learning from new data and clinical situations &#8211; under appropriate controls.</p>



<p>Implementing such solutions will, however, require significant investment in infrastructure and technology, as well as appropriate integration policies in healthcare facilities. Collaboration between all actors &#8211; scientists, physicians, regulators and technology manufacturers &#8211; will be crucial for the successful introduction of AI into healthcare.</p>



<h2 class="wp-block-heading"><strong>The human factor: improper use of medical AI tools</strong></h2>



<p>The role of the human factor in the use of AI in medicine cannot be underestimated. Even the most advanced algorithms are prone to error, and their effectiveness depends on proper use by end users, including doctors, other medical staff and patients. Without adequate understanding and skill, there is a risk that AI tools will be used incorrectly, leading to wrong diagnoses, treatment plans and clinical decisions that endanger patients&#8217; health.</p>



<p>Clinicians and medical staff must not only have access to AI technology but also be properly trained to use it. Current medical curricula often contain too little on artificial intelligence, leaving doctors to acquire new knowledge and skills quickly in order to use these tools effectively in practice. In addition, the absence of clinical experts from the design and development of AI technology can result in tools that are difficult to use and poorly matched to real clinical needs.</p>



<p>Patients, too, must be aware of and able to use medical AI appropriately. As more and more AI applications and tools become available to the general public, there is a risk that patients will rely on them without understanding their limitations and the uncertainty surrounding their accuracy. It is therefore important to inform patients about both the possibilities and the limits of AI in healthcare and to encourage a healthy, critical evaluation of the information these tools provide.</p>



<p>The development of medical AI applications also creates an urgent need for regulation and supervision. For years, many AI-based applications reached the market without sufficient evaluation of their clinical effectiveness and safety. The EU has now begun to close this gap: AI-enabled medical devices are subject to the Medical Devices Regulation (MDR), the AI Act (Regulation (EU) 2024/1689) classifies most of them as high-risk systems with phased-in obligations, and the European Health Data Space regulation sets rules for the secondary use of health data. Clear regulatory guidelines and assessment and approval procedures that reflect specific clinical and ethical requirements remain essential, however, and enhanced regulatory and supervisory efforts can help ensure that AI technologies are tailored to end-user needs and meet the highest standards of safety and effectiveness.</p>



<p>Ultimately, minimising the risk of error and misuse of medical AI requires the broad involvement of all stakeholders &#8211; physicians, medical staff, patients, regulators and technology manufacturers. Working together to develop, implement and evaluate AI in healthcare can benefit both patients and the healthcare system as a whole by improving diagnostic accuracy, treatment effectiveness and access to care.</p>



<h2 class="wp-block-heading"><strong>Bias: when AI reinforces health inequalities</strong></h2>



<p>Inequality in healthcare is a complex, multi-factor problem. Many people experience discrimination based on gender, age, ethnicity, socio-economic status or geographical location. These inequalities may be systemic, resulting from socio-economic neglect, lack of access to healthcare or direct discrimination by medical staff.</p>



<p>One of the main sources of these inequalities is human bias, which can lead to patients being treated differently on the basis of characteristics such as race or gender. Research conducted in the United States has shown that Black patients often receive inferior medical care compared with white patients. Similarly, women frequently experience delayed diagnoses for certain conditions, such as endometriosis, and their pain is more likely than men&#8217;s to be attributed to psychological causes.</p>



<p>The introduction of AI into healthcare seems promising, but without proper regulation it may exacerbate these inequalities. Medical algorithms can be biased because they are trained on data that is incomplete, unrepresentative or itself the product of biased decisions. If diagnostic algorithms are trained mainly on data from white patients, for example, they may be less effective at diagnosing disease in patients of other ethnic backgrounds. There is also a risk of perpetuating existing inequalities where AI models are trained on data that reflects them.</p>



<p>Addressing these issues requires close supervision and evaluation of medical algorithms and assurance that training data is representative and balanced across population characteristics such as race, gender, age and socio-economic status. It is also necessary to involve a broad range of experts &#8211; sociologists, biomedical ethicists, public health professionals and patients &#8211; to ensure that AI models are fair and effective for all social groups.</p>



<h2 class="wp-block-heading"><strong>The black box problem: lack of transparency</strong></h2>



<p>Amid growing interest in medical AI, an algorithm developed by Google for breast cancer screening sparked debate about the role these technologies can play in improving diagnosis and care. The algorithm delivered promising results, improving both the speed and reliability of screening and in some cases outperforming radiologists. Its ability to generalise to populations outside the regions on which it was trained attracted further interest.</p>



<p>The enthusiasm was accompanied by concern. The absence of details about the algorithm itself and of key technical descriptions led some to question the transparency and safety of the tool. This concern was echoed in the media and the AI community, where critics argued that a lack of full transparency could compromise both the usefulness and the safety of the algorithm.</p>



<p>Transparency in healthcare AI operates on two levels: traceability and explainability. Traceability refers to the documentation of the AI development process, including the model, the training data and post-deployment monitoring of the tool. In practice, existing tools are often delivered without full traceability, which undermines users&#8217; trust.</p>



<p>Explainability concerns the transparency of the decisions AI makes. In the case of algorithms based on deep neural networks, often referred to as &#8220;black boxes&#8221;, the absence of this transparency makes it difficult for clinicians and other stakeholders to understand the basis on which a decision was reached.</p>



<p>Various mitigation measures have been proposed to improve transparency and trust. An &#8220;AI passport&#8221; documenting key information about a model, together with tools for tracking the use of algorithms after deployment, could significantly improve traceability. Involving clinical end users from the earliest stages of algorithm development can also help develop effective strategies for explaining AI decisions.</p>



<p>Finally, regulators have an important role to play. By treating traceability and explainability as prerequisites for certification, they can set standards that encourage greater transparency in the development and application of AI algorithms in medicine.</p>



<h2 class="wp-block-heading"><strong>Privacy and data security</strong></h2>



<p>The growing use of AI in healthcare, particularly during and after the COVID-19 pandemic, has highlighted the risks to privacy, confidentiality and the protection of patient data. Lack of informed consent may lead to breaches such as the disclosure of protected data or the re-use of patient data for other purposes.</p>



<p>Opaque AI algorithms and complex consent forms limit patient autonomy and hinder shared decision-making with the physician. A well-known example is the 2016 case in which patient records held by a London NHS trust were transferred to DeepMind without the patients&#8217; informed consent.</p>



<p>AI in healthcare also carries the risk of data breaches, which can lead to identity theft and other cyberattacks. In 2020, for instance, a data breach at Cense AI exposed sensitive data relating to more than 2.5 million patients.</p>



<p>The re-use of data is a further risk, potentially leading to unauthorised use of patient data for purposes unrelated to healthcare. There is a need to raise awareness and skills regarding privacy and security risks and to extend the regulatory and legal framework. Support for decentralised approaches to AI and continued research into the security of cloud-based systems are also crucial.</p>



<h2 class="wp-block-heading"><strong>Who is responsible? The accountability gap</strong></h2>



<p>The concept of &#8220;algorithmic accountability&#8221; is gaining importance wherever AI is used, and especially in healthcare. It refers to the principle that people &#8211; not AI systems &#8211; are responsible for errors or improper actions of algorithms. The introduction of AI tools in medicine brings new challenges in this respect, and a sound solution to the question of responsibility is crucial for public acceptance of and trust in these technologies.</p>



<p>There is still considerable uncertainty as to who is responsible for AI-related medical errors, which calls for the adaptation of regulations and the legal framework to the specific characteristics of these technologies. One such challenge for policymakers and legislators is the &#8220;many hands&#8221; problem &#8211; the difficulty of allocating responsibility among the various entities involved in the development, implementation and use of AI. At EU level, the revised Product Liability Directive (Directive (EU) 2024/2853), which expressly covers software and AI systems, is a first step towards addressing this, while the proposed AI Liability Directive was withdrawn, leaving fault-based liability largely to national law.</p>



<p>A further difficulty lies in identifying the precise cause of an error involving medical AI. The cause may lie in the algorithm, in the data used to train it or in a misunderstanding of how the AI operates in clinical practice. The absence of uniform ethical and legal standards across the AI industry makes these problems harder to resolve.</p>



<p>Responsibility in medical AI is also closely linked to the clarity and transparency of algorithms: the less understandable an algorithm is, the harder it becomes to determine who is responsible. Proposals to address this include establishing processes that define the respective roles of AI developers and users, and setting up dedicated regulatory bodies.</p>



<h2 class="wp-block-heading"><strong>Barriers to implementation</strong></h2>



<p>Over the past five years, numerous medical AI algorithms have been proposed for a wide range of healthcare applications. Yet even where these technologies are clinically proven, safe and ethical, their implementation faces many practical obstacles. Healthcare professionals are often slow to adopt new technologies in daily practice. The implementation phase is critical, and beyond the creation of the algorithm itself, other factors must be taken into account, such as the limitations and quality of medical data and changes in the doctor-patient relationship.</p>



<p>The quality of medical data is essential for the effective use of medical AI, but such data is often unstructured and noisy. It must therefore be verified, quality-controlled and labelled, which requires considerable time and money. In addition, the introduction of AI may change the relationship between patients and healthcare professionals, creating new challenges in communicating disease risk information and updating clinical guidelines.</p>



<p>Bringing AI into clinical practice also requires interoperability and integration with existing health systems. Manufacturers and healthcare organisations will need to establish standard operating procedures and work together to ensure that new AI tools interoperate with existing technologies such as genetic sequencing and electronic patient records.</p>



<h2 class="wp-block-heading"><strong>Conclusion</strong></h2>



<p>The use of AI in medicine brings numerous benefits, but it also involves significant challenges and risks. Beyond technical aspects such as data quality and interoperability, changes in the relationship between patients and healthcare professionals and the need to update clinical guidelines must also be considered. Implementing AI in clinical practice requires collaboration between technology manufacturers and healthcare professionals to ensure the safe and effective integration of new tools into existing healthcare systems. Ultimately, a clear-eyed awareness of these risks is the precondition for harnessing the potential of AI to improve healthcare.</p>
<p> </p>




<p>Artykuł <a href="https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/artificial-intelligence-in-healthcare-the-risks-behind-the-promise/">Artificial Intelligence in Healthcare: the Risks Behind the Promise</a> pochodzi z serwisu <a href="https://www.kg-legal.eu">KIELTYKA GLADKOWSKI LEGAL | CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/artificial-intelligence-in-healthcare-the-risks-behind-the-promise/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Longevity Washing, AI and the Regulatory Fault Lines of the Longevity Industry: A European Perspective</title>
		<link>https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/longevity-washing-ai-and-the-regulatory-fault-lines-of-the-longevity-industry-a-european-perspective/</link>
					<comments>https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/longevity-washing-ai-and-the-regulatory-fault-lines-of-the-longevity-industry-a-european-perspective/#respond</comments>
		
		<dc:creator><![CDATA[jakub]]></dc:creator>
		<pubDate>Tue, 15 Sep 2026 19:35:31 +0000</pubDate>
				<category><![CDATA[PHARMACEUTICAL, HEALTHCARE & LIFE SCIENCES LAW]]></category>
		<category><![CDATA[AI Act]]></category>
		<category><![CDATA[Artificial intelligence]]></category>
		<category><![CDATA[EU Law]]></category>
		<category><![CDATA[EU Regulatory Law]]></category>
		<category><![CDATA[European Health Data Space]]></category>
		<category><![CDATA[Food Supplements]]></category>
		<category><![CDATA[gdpr]]></category>
		<category><![CDATA[Health Claims]]></category>
		<category><![CDATA[health tech]]></category>
		<category><![CDATA[Healthcare Law]]></category>
		<category><![CDATA[Life Sciences Law]]></category>
		<category><![CDATA[Longevity Industry]]></category>
		<category><![CDATA[Longevity Washing]]></category>
		<category><![CDATA[Medical Devices Regulation]]></category>
		<category><![CDATA[Novel Foods]]></category>
		<category><![CDATA[Pharmaceutical Law]]></category>
		<guid isPermaLink="false">https://www.kg-legal.eu/?p=8913</guid>

					<description><![CDATA[<p>Publication date: September 15, 2026 ABA ILS, Life Sciences and Healthcare Committee, September 2026Prepared by KIELTYKA GLADKOWSKI KG LEGAL I. Introduction The longevity economy is commonly estimated at several hundred billion dollars worldwide and continues to grow rapidly.[1] Venture capital flows into biotechnology companies that promise to slow, halt, or reverse aging. Clinics from Zurich [&#8230;]</p>
<p>Artykuł <a href="https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/longevity-washing-ai-and-the-regulatory-fault-lines-of-the-longevity-industry-a-european-perspective/">Longevity Washing, AI and the Regulatory Fault Lines of the Longevity Industry: A European Perspective</a> pochodzi z serwisu <a href="https://www.kg-legal.eu">KIELTYKA GLADKOWSKI LEGAL | CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p><mark style="background-color:rgba(0, 0, 0, 0)" class="has-inline-color has-vivid-cyan-blue-color"><strong>Publication date: September 15, 2026</strong></mark></p>



<figure class="wp-block-video"><video controls src="https://www.kg-legal.eu/wp-content/uploads/2026/09/ABA_Call_Longevity_Presentation-wrzesien.mp4"></video></figure>



<p class="has-luminous-vivid-amber-background-color has-background has-large-font-size">ABA ILS, Life Sciences and Healthcare Committee, September 2026Prepared by KIELTYKA GLADKOWSKI KG LEGAL</p>



<span id="more-8913"></span>



<p class="has-medium-font-size">I. Introduction</p>



<p>The longevity economy is commonly estimated at several hundred billion dollars worldwide and continues to grow rapidly.<a href="#_ftn1" id="_ftnref1">[1]</a> Venture capital flows into biotechnology companies that promise to slow, halt, or reverse aging. Clinics from Zurich to Seoul to Miami sell “longevity programmes.” Supplement brands attach the word “longevity” to products ranging from NAD precursors to collagen powders. And yet the word “longevity” does not exist as a legal category in European Union law. There is no definition, no register, no certification scheme, and no authority empowered to decide what may or may not describe itself as a longevity product, a longevity clinic, or a longevity company.</p>



<p>The gap between an enormous market and a non-existent legal definition is precisely where legal risk accumulates. Where there is no definition, there is classification risk, claims risk, and enforcement risk. There is also a phenomenon that this article, borrowing from the vocabulary of environmental marketing, calls “longevity washing.”</p>



<p>This article examines the longevity industry through the lens of EU regulatory law. The EU framework governs a market of some 450 million consumers and, because it is horizontal, sector-specific, and increasingly enforcement-oriented, it offers a useful point of comparison for practitioners in the United States, Asia, and Latin America. Part II explains why “longevity” is not a legal category and introduces the borderline-product problem that follows from that fact. Part III develops the concept of longevity washing and its consumer-facing, unfair-commercial-practice, and investor-facing dimensions. Part IV addresses the regulation of artificial intelligence in longevity research and diagnostics, including the revised timeline of the AI Act, the position of the European Medicines Agency on AI in the medicinal-product lifecycle, and the data-protection architecture formed by the GDPR and the European Health Data Space. Part V maps the sectoral “hot spots” across pharmaceuticals, medical devices, cosmetics, and food supplements. Part VI draws conclusions for practitioners.</p>



<h3 class="wp-block-heading">II. “Longevity” in the Eyes of the Law: The Borderline-Product Problem</h3>



<p>In EU regulatory law, aging is not a disease. The European Medicines Agency has never approved a medicinal product with “aging” as a therapeutic indication, and under Directive 2001/83/EC a medicinal product is defined by reference to the treatment or prevention of disease or the restoration, correction, or modification of physiological functions.<a href="#_ftn2" id="_ftnref2">[2]</a> The position in the United States is comparable. The long-running debate around the Targeting Aging with Metformin (TAME) trial illustrates the point: its designers had to negotiate a trial protocol with the Food and Drug Administration that targets aging indirectly, through a composite of age-related diseases, precisely because “aging” itself is not an approvable indication.<a href="#_ftn3" id="_ftnref3">[3]</a></p>



<p>The consequence is profound. A company cannot lawfully market a product “to treat aging.” The entire longevity industry therefore operates in the space of indirect claims: “supports healthy aging,” “promotes cellular health,” “extends healthspan.” Each of those phrases pushes the product toward one of several very different regulatory regimes.</p>



<p>This is the borderline-product problem, and it is the single most important legal concept in the sector. The same molecule – an NAD precursor, for example – may be: a medicinal product, if it is presented as treating or preventing disease or exerts a significant pharmacological, immunological, or metabolic effect; a food supplement under Directive 2002/46/EC;<a href="#_ftn4" id="_ftnref4">[4]</a> a novel food requiring pre-market authorisation under Regulation (EU) 2015/2283;<a href="#_ftn5" id="_ftnref5">[5]</a> a cosmetic under Regulation (EC) No 1223/2009, if applied to the skin with a claim limited to appearance;<a href="#_ftn6" id="_ftnref6">[6]</a> or a medical device. The last category is broader than it may appear: since the Medical Device Regulation (MDR) came into application, products listed in its Annex XVI – dermal fillers, certain energy-based aesthetic equipment – are regulated as devices even where they have no medical purpose at all.<a href="#_ftn7" id="_ftnref7">[7]</a></p>



<p>Classification does not follow the label a company chooses. It follows presentation, composition, and route of administration. The Court of Justice of the European Union has held for four decades that a product is a medicinal product “by presentation” where it is described or recommended as having properties for treating or preventing disease, irrespective of whether it actually has those properties; and that classification “by function” turns on a case-by-case scientific assessment of the product’s actual pharmacological, immunological, or metabolic action, not on the manufacturer’s intention.<a href="#_ftn8" id="_ftnref8">[8]</a> Marketing language alone can therefore reclassify a product and, with it, the entire compliance burden: marketing authorisation, good manufacturing practice, pharmacovigilance, and advertising restrictions.</p>



<p>When a client says “we are a longevity company,” the first question counsel should ask is: <em>which regime are you actually in?</em> “Longevity” is a marketing word. The law knows only medicines, devices, foods, and cosmetics.</p>



<h3 class="wp-block-heading">III. Longevity Washing: When the Claim Outruns the Science</h3>



<p>Greenwashing – claiming environmental virtue one does not have – is a familiar concept. Longevity washing is its younger sibling: labelling a product, a clinic, a research programme, or an entire company as “longevity-focused” when the science, the indication, or the business model does not support that description. The practice matters legally for three reasons.</p>



<h2 class="wp-block-heading"><em>A. Consumer-Facing Claims</em></h2>



<p>Under the Health Claims Regulation, any health claim made on a food – and food supplements are foods – must be specifically authorised and listed in the EU register.<a href="#_ftn9" id="_ftnref9">[9]</a> Claims such as “slows aging,” “supports cellular repair,” or “extends lifespan” are not authorised health claims. National authorities in the EU and the United Kingdom have treated phrases such as “cellular repair” and even “healthy aging” as impermissible where they imply a physiological mechanism or a reduction of disease risk. A substantial part of the longevity supplement market is thus operating with claims that would not survive enforcement scrutiny.</p>



<h2 class="wp-block-heading"><em>B. Unfair Commercial Practices and the Greenwashing Template</em></h2>



<p>The second layer is the general prohibition of misleading commercial practices under the Unfair Commercial Practices Directive (UCPD).<a href="#_ftn10" id="_ftnref10">[10]</a> Here the EU has recently built an entire enforcement architecture against greenwashing that repays close study by anyone advising on health claims. The Empowering Consumers for the Green Transition Directive amends the UCPD to prohibit generic environmental claims – “eco-friendly,” “climate-neutral” – unless the trader can demonstrate recognised excellent environmental performance, and it adds a series of specific greenwashing practices to the UCPD’s blacklist. Its provisions apply across the Union from 27 September 2026.<a href="#_ftn11" id="_ftnref11">[11]</a></p>



<p>The Directive should be read as a template. If “climate-neutral” now requires substantiation, it is a very short doctrinal step for regulators and courts to demand the same of “clinically proven to slow biological aging.” The methodology of anti-greenwashing enforcement – generic claim, absence of substantiation, misleading omission – maps directly onto longevity claims. The UCPD’s general clauses on misleading actions and omissions already provide the legal basis; what the green-claims reform supplies is a worked example of how those clauses can be operationalised against vague virtue-signalling.</p>



<h2 class="wp-block-heading"><em>C. Investor-Facing Washing</em></h2>



<p>The third dimension is of particular relevance to transactional lawyers. Start-ups increasingly brand themselves as “longevity biotech” because that is where the capital is, even when the underlying asset is a conventional dermatology product or a wellness application. For investors, this creates due-diligence risk: is the “longevity platform” in fact a regulated medicinal pipeline, with all the timeline and cost that implies, or a supplement business one enforcement letter away from relabelling? Misclassification discovered after investment is a valuation event. For the company, aggressive longevity framing in fundraising materials can generate liability under securities and misrepresentation rules in multiple jurisdictions. In due diligence on a longevity start-up, the regulatory classification memorandum is not an annex to the deal; it <em>is</em> the deal.</p>



<h3 class="wp-block-heading">IV. Artificial Intelligence in Longevity Research and Diagnostics</h3>



<p>The longevity field is arguably the most AI-dependent sector in the life sciences, for a simple reason: aging is not one target but thousands of interacting biological processes. A geroprotective drug cannot be designed the way an antibiotic is designed. The entire aging phenotype must be modelled, and that means machine learning on large multi-omic datasets. AI is not an add-on in longevity; it is the core methodology. That raises three distinct regulatory questions under EU law.</p>



<h2 class="wp-block-heading"><em>A. The AI Act</em></h2>



<p>Regulation (EU) 2024/1689, the AI Act, is the most comprehensive horizontal AI regulation in force anywhere and applies to almost every AI system used in the longevity value chain.<a href="#_ftn12" id="_ftnref12">[12]</a> It adopts a risk-based structure – prohibited practices, high-risk systems, transparency obligations, and minimal-risk systems – and the critical category for this sector is high-risk. An AI system that is itself a medical device, or a safety component of one, under the MDR or the In Vitro Diagnostic Regulation, and that is subject to third-party conformity assessment under those instruments, is high-risk under Article 6(1) and Annex I of the AI Act.<a href="#_ftn13" id="_ftnref13">[13]</a> This captures, for example, an AI tool that estimates a patient’s “biological age” from a blood panel and uses that estimate to guide a clinical intervention; an AI-driven diagnostic that predicts age-related disease risk; and the software layer of many longevity-clinic platforms once it makes a diagnostic or prognostic claim.</p>



<p>High-risk status is not a prohibition; it is a compliance regime. It requires a risk-management system, data governance with representative and bias-tested training data, technical documentation, logging, human oversight, transparency to deployers, accuracy, robustness and cybersecurity, a conformity assessment, and post-market monitoring.<a href="#_ftn14" id="_ftnref14">[14]</a> For most longevity start-ups this is a wholly new compliance layer on top of MDR conformity assessment, and the two must be coordinated.</p>



<p>The timeline has recently changed, and practitioners should update their advice accordingly. The original AI Act applied the high-risk obligations from 2 August 2026 for stand-alone systems listed in Annex III and from 2 August 2027 for AI embedded in products covered by Annex I, including medical devices. The Digital Omnibus on AI, adopted as Regulation (EU) 2026/1744 and in force since 27 July 2026, defers those dates to 2 December 2027 and 2 August 2028 respectively.<a href="#_ftn15" id="_ftnref15">[15]</a> The deferral does not lighten the substantive regime; the prohibitions in Article 5, the obligations of providers of general-purpose AI models, and the transparency obligations of Article 50 (which apply from 2 August 2026) are unaffected. For longevity companies whose AI is a medical device, the practical effect is a compliance window of roughly two years, during which harmonised standards and notified-body capacity are expected to mature. The window is an opportunity to design AI Act compliance into the MDR technical file from the outset rather than to defer the exercise.</p>



<h2 class="wp-block-heading"><em>B. AI in Drug Discovery and the European Medicines Agency</em></h2>



<p>The position for drug discovery is more nuanced. An AI model used purely internally to identify candidate molecules – the classic “AI for drug discovery” use case that dominates longevity-biotech pitch decks – is generally not, in itself, a high-risk AI system under the AI Act, because it does not make or materially influence decisions about individual patients. The regulatory question shifts instead to the European Medicines Agency. The EMA’s Reflection Paper on the use of AI in the medicinal product lifecycle sets out the Agency’s expectations from discovery through pharmacovigilance.<a href="#_ftn16" id="_ftnref16">[16]</a> Its core message is that the burden of proof rests on the sponsor to demonstrate that the AI model is fit for its regulatory purpose. That entails documented data provenance, model validation, a degree of explainability appropriate to the stage of development, and lifecycle management of the model itself.</p>



<p>If a longevity company tells its investors that “our AI discovered this molecule,” the regulator will eventually ask to see the model, the training data, and the validation. Vague AI claims in fundraising materials do not survive regulatory scrutiny and, increasingly, do not survive investor due diligence either.</p>



<h2 class="wp-block-heading"><em>C. Data: The GDPR and the European Health Data Space</em></h2>



<p>The third question concerns data, and it is here that longevity becomes uniquely difficult. Aging research is inherently longitudinal and multi-omic: genomic, epigenetic, and proteomic data, wearable data, and medical records, ideally across decades. Under the General Data Protection Regulation this is special-category data – health, genetic, and biometric data – and the available lawful bases are narrow.<a href="#_ftn17" id="_ftnref17">[17]</a> The scientific-research provisions of Article 9(2)(j) and Article 89 assist, but they are implemented differently in each Member State, which produces real fragmentation for pan-European longevity cohorts.</p>



<p>The European Health Data Space Regulation adds a second layer.<a id="_ftnref18" href="#_ftn18">[18]</a> It creates, for the first time, a mandatory EU-wide framework for the secondary use of electronic health data, administered by health-data-access bodies in each Member State. For longevity research the EHDS is potentially transformative, because it opens access to population-scale health data for research purposes. It also imposes strict conditions: purpose limitation, processing only within secure processing environments, a prohibition on re-identification, and specific prohibitions on using the data for advertising or marketing, for decisions detrimental to individuals such as insurance or employment decisions, or for developing products harmful to health.<a id="_ftnref19" href="#_ftn19">[19]</a> The secondary-use chapter applies from March 2029 for most data categories, but the lead time is short in the context of longitudinal cohorts. Longevity companies that intend to monetise health data – and many do – should be mapping their data flows against the EHDS regime now.</p>



<h3 class="wp-block-heading">V. Sector-by-Sector Regulatory Hot Spots</h3>



<p>Four sectoral silos together make up the longevity industry, and the same start-up frequently straddles two or three of them without realising it. In each silo, specific “hot spots” – advertising, manufacturing standards, registration, and market withdrawal – recur in practice.</p>



<h2 class="wp-block-heading"><em>A. Pharmaceuticals</em></h2>



<p>True longevity drugs – rapamycin analogues, senolytics, geroprotectors – sit squarely within Directive 2001/83/EC and its implementing rules, and will continue to do so under the new pharmaceutical package once it applies. Three practical hot spots stand out. First, off-label prescribing of rapamycin and metformin for longevity indications is widespread in private clinics across Europe. Off-label prescribing as such is a matter of clinical freedom, but off-label <em>promotion</em> by or on behalf of the marketing-authorisation holder is prohibited: advertising must conform to the summary of product characteristics, and advertising of unauthorised products or indications is not permitted.<a href="#_ftn20" id="_ftnref20">[20]</a> Longevity clinics are increasingly the vehicle through which promotional messaging reaches patients, and enforcement authorities have begun to take notice. Second, good manufacturing practice: anything presented as a medicine must be manufactured under an EU manufacturing authorisation and EU GMP, with qualified persons and full traceability; compounding pharmacies producing “longevity peptides” have become a significant enforcement target. Third, unlicensed importation: a large part of the longevity-peptide market operates through personal importation and grey channels, and customs enforcement across the EU has visibly tightened.</p>



<h2 class="wp-block-heading"><em>B. Medical Devices</em></h2>



<p>The MDR has fundamentally reshaped this space. Aesthetic devices – dermal fillers, energy-based devices used in longevity clinics, at-home devices marketed for “cellular rejuvenation” – are caught by Annex XVI even without a medical purpose. Three hot spots follow. Classification: many longevity wearables and applications become software as a medical device once they make a diagnostic or prognostic claim. Advertising: Article 7 of the MDR prohibits misleading claims and specifically prohibits ascribing to a device functions and properties it does not have, which operates in practice as a codified anti-washing rule for devices.<a href="#_ftn21" id="_ftnref21">[21]</a> Registration and vigilance: the first four modules of the EUDAMED database – actor registration, UDI/device registration, notified bodies and certificates, and market surveillance – have been mandatory since 28 May 2026, with legacy devices to be registered by 28 November 2026; the vigilance module is not yet mandatory, so serious incidents and field safety corrective actions continue to be reported to national competent authorities.<a href="#_ftn22" id="_ftnref22">[22]</a> Market withdrawals happen: a device sold as a “cellular biomarker analyser” without valid clinical evidence can be removed from the market by any national competent authority, and the MDR’s market-surveillance coordination means that one withdrawal can cascade across the Union.</p>



<h2 class="wp-block-heading"><em>C. Cosmetics and Aesthetic Products</em></h2>



<p>The Cosmetics Regulation governs anti-aging creams, serums, and topical actives. Two hot spots dominate. The first is the Product Information File: the responsible person must hold a complete file including a safety assessment and substantiation of every claim. The second is the Claims Regulation, Commission Regulation (EU) No 655/2013, with its six common criteria: legal compliance, truthfulness, evidential support, honesty, fairness, and informed decision-making.<a href="#_ftn23" id="_ftnref23">[23]</a> A claim such as “reverses skin aging at the cellular level” fails the evidential-support criterion unless a robust dossier stands behind it. Enforcement is largely national, but the Cosmetic Products Notification Portal is EU-wide, and non-compliant products are routinely notified through the Safety Gate rapid-alert system.</p>



<h2 class="wp-block-heading"><em>D. Food Supplements and Novel Foods</em></h2>



<p>It is in the food and supplement space that the longevity industry is most creative and most exposed. Directive 2002/46/EC governs vitamins and minerals in supplements; everything else falls under the general food law of Regulation (EC) No 178/2002<a href="#_ftn24" id="_ftnref24">[24]</a> and, critically, the Novel Food Regulation. Nicotinamide mononucleotide (NMN), one of the most heavily marketed longevity molecules, is the paradigmatic case. NMN is treated as a novel food in the EU, which means it cannot lawfully be placed on the market as a supplement without pre-market authorisation by the Commission following an EFSA safety assessment. Nicotinamide riboside received such an authorisation in 2020.<a href="#_ftn25" id="_ftnref25">[25]</a> NMN has not – although the picture is now moving. In March 2026 EFSA’s NDA Panel adopted a positive opinion on the safety of β-NMN in food supplements at up to 300 mg per day for adults, and the opinion was published in May 2026.<a href="#_ftn26" id="_ftnref26">[26]</a> An EFSA opinion is a scientific assessment, not an authorisation; the Commission must still adopt an implementing act adding NMN to the Union list, and where the applicant has requested data protection the authorisation will initially be proprietary to that applicant’s specification. Until that act is adopted, NMN products on the shelves of European longevity clinics remain unauthorised novel foods. That is not a grey area; it is a non-compliant market operating in plain sight, and it is the kind of enforcement pipeline that eventually produces high-profile withdrawal actions. Once the Health Claims Regulation is added to the picture, the conclusion is unavoidable: the food and supplement leg of the longevity industry is the most legally exposed part of the entire sector.</p>



<h1 class="wp-block-heading">VI. Conclusions</h1>



<p>The longevity industry is a genuine scientific and commercial phenomenon, and much of the underlying research is serious. But lawyers advising companies, investors, clinicians, and, increasingly, regulators in this space must see it clearly: “longevity” is not a legal category. It is a marketing frame layered on top of four very different regulatory regimes. Three practical conclusions follow for anyone whose product touches European consumers.</p>



<p>First, always begin with classification. The word “longevity” conveys nothing about the applicable regime. Ask what the product is, how it is presented, and what it does, and let the regulatory regime follow from those answers.</p>



<p>Second, treat longevity claims the way green claims are now treated. The direction of enforcement is unmistakable. The Empowering Consumers for the Green Transition Directive, applicable from 27 September 2026, gives regulators a sharpened toolkit that will, sooner or later, be pointed at health and wellness claims. Substantiation is no longer optional.</p>



<p>Third, integrate AI Act compliance with sectoral compliance from the outset. For any longevity venture using AI in diagnostics or patient-facing decision support, the AI Act, the MDR, and the GDPR, soon joined by the European Health Data Space, form a single interlocking compliance architecture. The deferral of the AI Act’s high-risk obligations to 2027 and 2028 is a design window, not a reprieve. Retrofitting is expensive; designing for compliance is not.</p>



<p>The longevity industry will keep growing, and regulators will keep catching up. The lawyers who understand both the science and the sectoral map will be the ones clients call first.</p>



<hr class="wp-block-separator has-alpha-channel-opacity"/>



<p><a href="#_ftnref1" id="_ftn1">[1]</a> Longevity economy estimates vary widely by definition; see, e.g., the periodic longevity-market reports of Bank of America Global Research and McKinsey Health Institute. The figure is offered here as an order of magnitude, not a precise valuation.</p>



<p><a href="#_ftnref2" id="_ftn2">[2]</a> Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community Code Relating to Medicinal Products for Human Use, art. 1(2), 2001 O.J. (L 311) 67 [hereinafter Directive 2001/83]. At the time of writing, the new EU pharmaceutical package (a new directive on the Union code for medicinal products for human use and a new regulation on Union authorisation procedures) has been politically agreed and is in the final stage of formal adoption; the substantive rules discussed here are carried over into the new framework, which will apply after a transitional period of approximately two years from entry into force.</p>



<p><a href="#_ftnref3" id="_ftn3">[3]</a> See Nir Barzilai et al., Metformin as a Tool to Target Aging, 23 Cell Metabolism 1060 (2016) (describing the design of the Targeting Aging with Metformin (TAME) trial around a composite of age-related diseases).</p>



<p><a href="#_ftnref4" id="_ftn4">[4]</a> Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the Approximation of the Laws of the Member States Relating to Food Supplements, 2002 O.J. (L 183) 51.</p>



<p><a href="#_ftnref5" id="_ftn5">[5]</a> Regulation (EU) 2015/2283 of the European Parliament and of the Council of 25 November 2015 on Novel Foods, 2015 O.J. (L 327) 1 [hereinafter Novel Food Regulation].</p>



<p><a href="#_ftnref6" id="_ftn6">[6]</a> Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on Cosmetic Products, 2009 O.J. (L 342) 59 [hereinafter Cosmetics Regulation].</p>



<p><a href="#_ftnref7" id="_ftn7">[7]</a> Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on Medical Devices, Annex XVI, 2017 O.J. (L 117) 1 [hereinafter MDR]; Commission Implementing Regulation (EU) 2022/2346 of 1 December 2022 Laying Down Common Specifications for the Groups of Products Without an Intended Medical Purpose Listed in Annex XVI, 2022 O.J. (L 311) 60.</p>



<p><a href="#_ftnref8" id="_ftn8">[8]</a> Case 227/82, Van Bennekom, ECLI:EU:C:1983:354 (establishing that a product is a medicinal product “by presentation” where it is described or recommended as having therapeutic or prophylactic properties, irrespective of its actual efficacy); Case C-319/05, Comm’n v. Germany, ECLI:EU:C:2007:678 (garlic capsules); Case C-140/07, Hecht-Pharma GmbH v. Staatliches Gewerbeaufsichtsamt Luneburg, ECLI:EU:C:2009:5 (classification “by function” requires a case-by-case assessment of pharmacological, immunological or metabolic properties). See also Directive 2001/83, supra note 2, art. 2(2) (in cases of doubt, the medicinal-products regime prevails).</p>



<p><a href="#_ftnref9" id="_ftn9">[9]</a> Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on Nutrition and Health Claims Made on Foods, arts. 10, 13, 14, 2006 O.J. (L 404) 9 [hereinafter Health Claims Regulation]. The EU Register of nutrition and health claims is maintained by the European Commission.</p>



<p><a href="#_ftnref10" id="_ftn10">[10]</a> Directive 2005/29/EC of the European Parliament and of the Council of 11 May 2005 Concerning Unfair Business-to-Consumer Commercial Practices in the Internal Market, 2005 O.J. (L 149) 22 [hereinafter UCPD].</p>



<p><a href="#_ftnref11" id="_ftn11">[11]</a> Directive (EU) 2024/825 of the European Parliament and of the Council of 28 February 2024 Amending Directives 2005/29/EC and 2011/83/EU as Regards Empowering Consumers for the Green Transition, OJ L, 2024/825, 6.3.2024 [hereinafter ECGT Directive]. Member States were required to transpose the Directive by 27 March 2026; its provisions apply from 27 September 2026. The separate Green Claims Directive proposal, which would have introduced ex ante verification of explicit environmental claims, was withdrawn by the Commission in 2025 and is not discussed here.</p>



<p><a href="#_ftnref12" id="_ftn12">[12]</a> Regulation (EU) 2024/1689 of the European Parliament and of the Council of 13 June 2024 Laying Down Harmonised Rules on Artificial Intelligence, OJ L, 2024/1689, 12.7.2024 [hereinafter AI Act].</p>



<p><a href="#_ftnref13" id="_ftn13">[13]</a> AI Act, supra note 12, art. 6(1) &amp; Annex I, § A (listing the MDR and Regulation (EU) 2017/746 on in vitro diagnostic medical devices). The Annex I route applies where the AI system is a product, or a safety component of a product, that is itself subject to third-party conformity assessment under the listed Union harmonisation legislation.</p>



<p><a href="#_ftnref14" id="_ftn14">[14]</a> AI Act, supra note 12, arts. 9–15, 17, 43, 72.</p>



<p><a href="#_ftnref15" id="_ftn15">[15]</a> Regulation (EU) 2026/1744 of the European Parliament and of the Council Amending Regulation (EU) 2024/1689 as Regards the Simplification of Certain Obligations (“Digital Omnibus on AI”), OJ L, 2026/1744, 24.7.2026 (in force 27 July 2026). The Regulation defers the high-risk obligations for stand-alone (Annex III) systems to 2 December 2027 and for AI embedded in products covered by Annex I, including medical devices, to 2 August 2028; the Article 50 transparency obligations continue to apply from 2 August 2026.</p>



<p><a href="#_ftnref16" id="_ftn16">[16]</a> Eur. Medicines Agency, Reflection Paper on the Use of Artificial Intelligence (AI) in the Medicinal Product Lifecycle, EMA/CHMP/CVMP/83833/2023 (adopted Sept. 2024).</p>



<p><a href="#_ftnref17" id="_ftn17">[17]</a> Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the Protection of Natural Persons with Regard to the Processing of Personal Data, arts. 9(2)(j), 89, 2016 O.J. (L 119) 1 [hereinafter GDPR].</p>



<p><a href="#_ftnref18" id="_ftn18">[18]</a> Regulation (EU) 2025/327 of the European Parliament and of the Council of 11 February 2025 on the European Health Data Space, OJ L, 2025/327, 5.3.2025 [hereinafter EHDS Regulation]. The Regulation entered into force on 26 March 2025 and applies in stages: most provisions from 26 March 2027, and the core secondary-use chapter from 26 March 2029 (2031 for certain data categories). See id. art. 105.</p>



<p><a href="#_ftnref19" id="_ftn19">[19]</a> EHDS Regulation, supra note 18, arts. 50–54 (secure processing environments; permitted and prohibited purposes of secondary use).</p>



<p><a href="#_ftnref20" id="_ftn20">[20]</a> Directive 2001/83, supra note 2, art. 87(2) (all parts of advertising must comply with the particulars listed in the summary of product characteristics), arts. 40–53 (manufacturing authorisation and good manufacturing practice) and art. 87(1) (prohibition of advertising of medicinal products without a marketing authorisation).</p>



<p><a href="#_ftnref21" id="_ftn21">[21]</a> MDR, supra note 7, art. 7.</p>



<p><a href="#_ftnref22" id="_ftn22">[22]</a> Commission Decision (EU) 2025/2371 of 26 November 2025 (declaring the first four EUDAMED modules functional), OJ L, 2025/2371, 27.11.2025; Regulation (EU) 2024/1860 of the European Parliament and of the Council of 13 June 2024, OJ L, 2024/1860, 9.7.2024 (gradual roll-out of EUDAMED). The four modules (actor registration, UDI/device registration, notified bodies and certificates, market surveillance) are mandatory from 28 May 2026; legacy devices remaining on the market must be registered by 28 November 2026. The vigilance and clinical-investigation modules are not yet mandatory, and serious incidents continue to be reported to national competent authorities.</p>



<p><a href="#_ftnref23" id="_ftn23">[23]</a> Cosmetics Regulation, supra note 6, arts. 11, 13, 20; Commission Regulation (EU) No 655/2013 of 10 July 2013 Laying Down Common Criteria for the Justification of Claims Used in Relation to Cosmetic Products, Annex, 2013 O.J. (L 190) 31.</p>



<p><a href="#_ftnref24" id="_ftn24">[24]</a> Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 Laying Down the General Principles and Requirements of Food Law, 2002 O.J. (L 31) 1.</p>



<p><a href="#_ftnref25" id="_ftn25">[25]</a> Commission Implementing Regulation (EU) 2020/16 of 10 January 2020 Authorising the Placing on the Market of Nicotinamide Riboside Chloride as a Novel Food, 2020 O.J. (L 7) 6.</p>



<p><a id="_ftn26" href="#_ftnref26">[26]</a> EFSA Panel on Nutrition, Novel Foods and Food Allergens, Safety of Beta-Nicotinamide Mononucleotide (β-NMN) Pursuant to Regulation (EU) 2015/2283 and the Bioavailability of Nicotinamide from This Source in the Context of Directive 2002/46/EC, 24 EFSA J. e10007 (2026) (opinion adopted 4 March 2026, published 11 May 2026). Authorisation requires a Commission implementing act amending the Union list established by Commission Implementing Regulation (EU) 2017/2470; at the time of writing no such act has been published, and any authorisation granted on the basis of proprietary data will initially benefit only the applicant. See Novel Food Regulation, supra note 5, arts. 12, 26.</p>
<p> </p>



<p>#LongevityIndustry #LongevityWashing #EURegulatoryLaw #ArtificialIntelligence #AIAct #HealthcareLaw #LifeSciencesLaw #HealthTech #MedicalDevices #PharmaceuticalLaw #GDPR #EuropeanHealthDataSpace #EUlaw #HealthClaims #NovelFoods</p>


<p>Artykuł <a href="https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/longevity-washing-ai-and-the-regulatory-fault-lines-of-the-longevity-industry-a-european-perspective/">Longevity Washing, AI and the Regulatory Fault Lines of the Longevity Industry: A European Perspective</a> pochodzi z serwisu <a href="https://www.kg-legal.eu">KIELTYKA GLADKOWSKI LEGAL | CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/longevity-washing-ai-and-the-regulatory-fault-lines-of-the-longevity-industry-a-european-perspective/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		<enclosure url="https://www.kg-legal.eu/wp-content/uploads/2026/09/ABA_Call_Longevity_Presentation-wrzesien.mp4" length="12991488" type="video/mp4" />

			</item>
		<item>
		<title>Biostimulants under the microscope of the law – where does information end and prohibited advertising of medical devices begin?</title>
		<link>https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/biostimulants-under-the-microscope-of-the-law-where-does-information-end-and-prohibited-advertising-of-medical-devices-begin/</link>
					<comments>https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/biostimulants-under-the-microscope-of-the-law-where-does-information-end-and-prohibited-advertising-of-medical-devices-begin/#respond</comments>
		
		<dc:creator><![CDATA[jakub]]></dc:creator>
		<pubDate>Fri, 24 Jul 2026 15:14:06 +0000</pubDate>
				<category><![CDATA[PHARMACEUTICAL, HEALTHCARE & LIFE SCIENCES LAW]]></category>
		<category><![CDATA[aesthetic medicine]]></category>
		<category><![CDATA[digital health]]></category>
		<category><![CDATA[EU healthcare]]></category>
		<category><![CDATA[eu regulation]]></category>
		<category><![CDATA[health tech]]></category>
		<category><![CDATA[healthcare compliance]]></category>
		<category><![CDATA[healthcare innovation]]></category>
		<category><![CDATA[Healthcare Law]]></category>
		<category><![CDATA[kglegal]]></category>
		<category><![CDATA[Legal Compliance]]></category>
		<category><![CDATA[Life Sciences]]></category>
		<category><![CDATA[Life Sciences Law]]></category>
		<category><![CDATA[MDR]]></category>
		<category><![CDATA[medical device advertising]]></category>
		<category><![CDATA[Medical Device Regulation]]></category>
		<category><![CDATA[Medical devices]]></category>
		<category><![CDATA[MedTech]]></category>
		<category><![CDATA[MedTech compliance]]></category>
		<category><![CDATA[pharma and healthcare]]></category>
		<category><![CDATA[Regulatory Affairs]]></category>
		<category><![CDATA[Regulatory Compliance]]></category>
		<guid isPermaLink="false">https://www.kg-legal.eu/?p=8836</guid>

					<description><![CDATA[<p>Publication date: July 24, 2026 Biostimulants in aesthetic medicine – current regulatory challenges for manufacturers, distributors and clinics The aesthetic medicine market is currently one of the fastest-growing healthcare segments in Europe. Particularly dynamic growth is observed in so-called tissue biostimulants, preparations used to stimulate the body&#8217;s natural regenerative processes. While traditional fillers dominated just [&#8230;]</p>
<p>Artykuł <a href="https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/biostimulants-under-the-microscope-of-the-law-where-does-information-end-and-prohibited-advertising-of-medical-devices-begin/">Biostimulants under the microscope of the law – where does information end and prohibited advertising of medical devices begin?</a> pochodzi z serwisu <a href="https://www.kg-legal.eu">KIELTYKA GLADKOWSKI LEGAL | CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p><strong><mark style="background-color:rgba(0, 0, 0, 0)" class="has-inline-color has-vivid-cyan-blue-color">Publication date: July 24, 2026</mark></strong></p>



<h2 class="wp-block-heading"><strong>Biostimulants in aesthetic medicine – current regulatory challenges for manufacturers, distributors and clinics</strong></h2>



<p id="ember53">The aesthetic medicine market is currently one of the fastest-growing healthcare segments in Europe. Particularly dynamic growth is observed in so-called tissue biostimulants, preparations used to stimulate the body&#8217;s natural regenerative processes. While traditional fillers dominated just a few years ago, today both manufacturers and physicians are increasingly turning to preparations containing poly-L-lactic acid (PLLA), calcium hydroxyapatite, polynucleotides, and collagen preparations, whose mechanism of action is based on the stimulation of tissue regeneration processes rather than solely on mechanical effects.</p>



<span id="more-8836"></span>



<p id="ember54">The growing popularity of these products, however, raises a number of legal questions. These concern not only their qualification as medical devices, but primarily the manner of communicating their properties and permissible forms of promotion. In practice, manufacturers, importers, distributors, and aesthetic medicine clinics increasingly face the dilemma of drawing the line between providing reliable product information and advertising, which is subject to stringent legal restrictions.</p>



<p id="ember55">This issue has become particularly important following the entry into force of the Act of April 7, 2022, on Medical Devices and the issuance of the Regulation of the Minister of Health on the Advertising of Medical Devices. Polish legislators have decided to introduce some of the most detailed regulations regarding the advertising of medical devices in Europe. These restrictions directly impact the activities of manufacturers, distributors, importers, healthcare providers, and marketing agencies serving the aesthetic medicine industry.</p>



<p id="ember56">At the same time, it&#8217;s important to remember that advertising medical devices does not operate in isolation from other legal regulations. Businesses must consider not only the provisions of Regulation (EU) 2017/745 on medical devices (MDR) and the Medical Devices Act, but also regulations on consumer protection, combating unfair market practices, combating unfair competition, personal data protection, and sometimes regulations governing the practice of medical professions and healthcare activities. Consequently, a single marketing campaign may be subject to simultaneous assessment under several different legal regimes.</p>



<p id="ember57">Particular difficulties arise with products used exclusively by individuals with appropriate professional qualifications. In practice, most biostimulants are administered via injection by a physician or other qualified medical professional. This raises the question of whether products intended exclusively for professional use can be advertised at all, and if not, how can businesses legally present information about their offerings on websites, social media, or at industry conferences.</p>



<p id="ember58">The purpose of this study is to present practical aspects of applying regulations regarding the advertising of medical devices, using tissue biostimulants as an example. Particular attention will be paid to the boundary between advertising and information, the obligations of manufacturers and distributors, the most common marketing errors, and compliance solutions that can reduce the risk of violating applicable regulations.</p>



<h2 class="wp-block-heading" id="ember59">Biostimulants – why do they raise so much legal controversy?</h2>



<p id="ember60">From a legal perspective, biostimulants constitute one of the most interesting categories of medical devices. Their specificity lies in the fact that, although formally subject to regulations specific to medical devices, their method of use, risk profile, and patient perception often resemble medicinal products more than traditional medical devices.</p>



<p id="ember61">In market practice, patients often fail to recognize the difference between a medicinal product and a biostimulant. Both types of products are administered in a doctor&#8217;s office, require medical qualifications, involve intervention in the body, and may cause adverse reactions. Therefore, for the average consumer, the difference between a medicinal product and a medical device remains almost invisible.</p>



<p id="ember62">From the perspective of EU law, however, what matters most is not the method of administration or the site of use, but the mechanism by which the principal intended action is achieved. The MDR is based on a fundamental distinction between medicinal products and medical devices. If the principal action is achieved by pharmacological, immunological, or metabolic means, the product will generally be classified as a medicinal product. However, if the mechanism of action is based on other properties &#8211; for example, physical or mechanical &#8211; the product may be classified as a medical device, even if its use leads to long-term biological effects.</p>



<p id="ember63">This very boundary has been the subject of numerous interpretational disputes for years. In the case of biostimulants, the preparation does not replace natural processes occurring in the body nor does it produce a therapeutic effect through a pharmacological mechanism. Its purpose is to create conditions enabling the activation of natural regenerative processes, such as stimulating fibroblasts to produce collagen or rebuilding the extracellular matrix. It is this mechanism that causes most currently available biostimulants to be classified as medical devices.</p>



<p id="ember64">This does not mean, however, that all products marketed as &#8220;biostimulants&#8221; automatically fall into the same regulatory category. Legal classification is determined by a case-by-case analysis of the specific product, its intended use, and the mechanism of action specified by the manufacturer. In practice, there are also products that, despite similar aesthetic applications, may be subject to different legal regimes, including regulations concerning medicinal products, cosmetics, and medical devices.</p>



<p id="ember65">This is fundamental for subsequent marketing communications. Already at the product qualification stage, the manufacturer should consider the target audience, the information that can be conveyed to recipients, and the advertising restrictions that will apply. Mistakes made at this stage often result in the need to redesign the entire marketing strategy after the product has been launched.</p>



<h2 class="wp-block-heading" id="ember66">Can biostimulants be advertised? Limitations under the Medical Devices Act and the MDR Regulation</h2>



<p id="ember67">One of the most frequently asked questions by manufacturers, importers, and healthcare providers is whether biostimulants can be advertised to a broad audience. The answer to this question is ambiguous and requires consideration of both the provisions of the EU MDR Regulation, the Polish Medical Devices Act, and implementing regulations governing advertising.</p>



<p id="ember68">In practice, a certain pattern can be observed. Many entrepreneurs equate the fact that a product has been legally introduced to the market with the ability to freely promote it. However, this assumption is incorrect. Approval of a medical device for marketing does not automatically mean that the manufacturer or distributor can use any marketing tools. On the contrary, the more specialized the product and the greater the risk associated with its use, the greater the restrictions on its communication.</p>



<p id="ember69">In the case of biostimulants, it is particularly important that the vast majority of these products are intended for use only by individuals with appropriate professional qualifications. Treatments using them require medical qualification, maintaining appropriate aseptic conditions, and injections performed in accordance with medical knowledge. Therefore, the recipient of the product is not the patient, but a medical professional who then uses the product while providing healthcare services or aesthetic medicine treatments.</p>



<p id="ember70">This circumstance is of fundamental importance from the perspective of advertising law.</p>



<h2 class="wp-block-heading" id="ember71">Advertising of medical devices is not advertising of consumer products.</h2>



<p id="ember72">The Medical Devices Act adopts different assumptions than the regulations governing the advertising of ordinary consumer goods. The legislator&#8217;s goal was not to create freedom in marketing activities, but to ensure that decisions regarding the use of medical devices are made primarily based on medical knowledge, not advertising messages.</p>



<p id="ember73">For this reason, the legislator decided to introduce numerous restrictions on both the content of advertising and its target audience. In practice, this means that, already at the design stage of a marketing campaign, entrepreneurs should answer three fundamental questions:</p>



<ul class="wp-block-list">
<li>who is the actual user of the product,</li>



<li>to whom the message is addressed,</li>



<li>whether the information provided is of a promotional nature or purely informational.</li>
</ul>



<p id="ember75">Only a combined analysis of these elements allows us to assess the compliance of the planned communication with applicable regulations.</p>



<h2 class="wp-block-heading" id="ember76">The intended use of the product is crucial.</h2>



<p id="ember77">In practice, there&#8217;s a common misconception that advertising opportunities are determined solely by how a product is sold. This isn&#8217;t the correct approach.</p>



<p id="ember78">The manufacturer&#8217;s intended use of the product and the user group specified in the technical documentation and instructions for use are of much greater importance. If the manufacturer has specified that the product should only be used by professionals, this also influences the assessment of the admissibility of directing marketing messages to individuals without medical qualifications.</p>



<p id="ember79">This is precisely the situation with most biostimulants. These products are intended for procedures requiring appropriate professional training, knowledge of anatomy, aseptic techniques, and the ability to recognize contraindications. From a regulatory perspective, it would be difficult to justify extensive advertising campaigns aimed at the general public when the product itself cannot be used independently by the average consumer.</p>



<p id="ember80">This doesn&#8217;t mean, however, that businesses cannot provide any information regarding such products. On the contrary, the law permits the provision of information about medical devices, but the line between information and advertising requires individual assessment.</p>



<h2 class="wp-block-heading" id="ember81">Advertising and information – why is the distinction so important?</h2>



<p id="ember82">In practice, the vast majority of disputes concerning medical device advertising do not focus on obvious promotional campaigns. Much more often, the problem arises with materials that businesses define as &#8220;informational,&#8221; while from the perspective of regulatory authorities, they may be considered advertising.</p>



<p id="ember83">Importantly, neither the MDR nor the Medical Devices Act provide a legal definition of medical device advertising. However, the lack of a statutory definition does not imply any freedom of interpretation. Case law and doctrine assume that the nature of a message is primarily determined by its actual purpose, not the name given to it by the trader.</p>



<p id="ember84">If the primary purpose of the message is to increase interest in the product, build a positive image of the product or encourage its purchase or use, there is a high probability that the message will be classified as advertising, regardless of whether it contains a direct call to purchase.</p>



<p id="ember85">In practice, this means that even seemingly neutral materials may be considered advertising if they are prepared in a way that highlights only the advantages of the product, ignores its limitations or uses characteristic marketing techniques.</p>



<h2 class="wp-block-heading" id="ember86">Is the manufacturer&#8217;s website itself an advertisement?</h2>



<p id="ember87">This is one of the most frequently asked questions in the practice of law firms advising manufacturers of medical devices.</p>



<p id="ember88">There is no single universal answer to this question.</p>



<p id="ember89">The mere presence of product information on a website does not constitute advertising. A website can function as a product catalog, a database of technical documentation, or a platform for communicating with medical professionals. However, if the product&#8217;s presentation goes beyond providing objective information and begins to utilize typical marketing mechanisms, the risk of such communication being classified as advertising significantly increases.</p>



<p id="ember90">For example, posting instructions for use, declarations of conformity, technical data, or information on how to use a product on a website will generally be informative. However, a situation in which the same website includes slogans such as &#8220;revolutionary rejuvenation method,&#8221; &#8220;the most effective biostimulator available on the market,&#8221; &#8220;instant lifting effect,&#8221; or &#8220;spectacular results guaranteed&#8221; should be assessed differently. In such cases, the message goes beyond neutral information and begins to serve a promotional purpose.</p>



<p id="ember91">Therefore, designing websites for medical device manufacturers requires close collaboration between marketing departments and legal and regulatory affairs departments . In practice, even seemingly minor changes in product presentation can result in a different legal classification for the entire message.</p>



<h2 class="wp-block-heading" id="ember92">The boundary between advertising and information – practical problems of producers and aesthetic medicine clinics</h2>



<p id="ember93">While the distinction between advertising and information seems intuitive, in practice it is one of the most problematic issues related to the functioning of the medical device market. This stems primarily from the fact that contemporary marketing communication rarely takes the form of classic television or print advertising. Businesses much more frequently utilize websites, social media, newsletters, podcasts, webinars , expert blogs, and educational materials. Each of these forms can—depending on how it is prepared—be considered both neutral information and advertising.</p>



<p id="ember94">In practice, there is no single element that automatically determines the classification of a given message. Supervisory authorities and courts analyze all the circumstances, taking into account the content of the message, its form, presentation, audience, and the actual purpose of the publication. This means that even a message containing only truthful information may be considered advertising if its primary purpose is to encourage the purchase or use of a product.</p>



<p id="ember95">For this reason, businesses should move away from the simple question: &#8220;Are we allowed to publish this information?&#8221; and instead ask themselves: &#8220;How will the average recipient perceive this message?&#8221; It is the recipient&#8217;s perspective, not the business&#8217;s intention, that will in many cases determine the legality of the message.</p>



<h2 class="wp-block-heading" id="ember96">Website – an entrepreneur&#8217;s business card or an advertising tool?</h2>



<p id="ember97">The first place where doubts arise is almost always the manufacturer&#8217;s, distributor&#8217;s, or clinic&#8217;s website. For many businesses, it is their primary channel of communication with the market, yet it is also one of the most frequently scrutinized elements during inspections conducted by regulatory authorities.</p>



<p id="ember98">The mere presence of information about a medical device on a website is not prohibited. Businesses have the right to present information about the products offered, their properties, methods of use, technical documentation, and instructions for use. However, problems arise when the presentation method goes beyond providing objective information.</p>



<p id="ember99">A good example is comparing two descriptions of the same product.</p>



<p id="ember100">The first one could be as follows:</p>



<p id="ember101">&#8220;A preparation intended for the reconstruction of tissue volume in accordance with the instructions for use. The product is intended for use by qualified medical professionals.&#8221;</p>



<p id="ember102">This description is for informational purposes only. It is limited to presenting the product&#8217;s intended use and user group.</p>



<p id="ember103">The following message should be assessed differently:</p>



<p id="ember104">&#8220;The most innovative biostimulator on the market. It instantly rejuvenates the skin and provides a spectacular lifting effect after just one treatment.&#8221;</p>



<p id="ember105">Although both messages refer to the same product, the second employs typical marketing tactics. It uses evaluative terms (&#8220;the most innovative,&#8221; &#8220;spectacular effect&#8221;), promises of effectiveness, and suggests a competitive advantage. This type of message is difficult to consider as neutral technical information.</p>



<p id="ember106">In practice, this means that entrepreneurs should analyze not only the content of the information, but also the way it is expressed. Often, it is individual marketing terms that determine the overall nature of the message.</p>



<h2 class="wp-block-heading" id="ember107">Newsletters and mailings to customers</h2>



<p id="ember108">Another tool increasingly used by manufacturers and distributors is newsletters and emails directed to customers. Again, not every message can be considered advertising.</p>



<p id="ember109">If a newsletter contains information about changes in regulations, new regulatory requirements, announcements from supervisory authorities, or changes to product instructions, it will generally serve an informative purpose. However, messages whose primary purpose is to increase sales of a specific product should be assessed differently.</p>



<p id="ember110">For example, a message titled &#8220;Changes to MDR requirements for technical documentation&#8221; would be educational in nature. An email with the slogan &#8220;Discover the most effective biostimulant available on the market – order today&#8221; would undoubtedly serve an advertising function.</p>



<p id="ember111">This does not, of course, prohibit commercial communication. However, entrepreneurs should remember that such communication is subject to all restrictions applicable to advertising medical devices.</p>



<h2 class="wp-block-heading" id="ember112">Webinars and training – education or product promotion?</h2>



<p id="ember113">The significant increase in the popularity of webinars organized by medical device manufacturers has also led to this form of communication starting to attract the attention of supervisory authorities.</p>



<p id="ember114">Organizing training for doctors and other medical professionals is nothing unusual. On the contrary, in many cases, proper user training is an essential element in ensuring the safe use of a device.</p>



<p id="ember115">The problem arises, however, when a webinar described as a &#8220;scientific training&#8221; actually focuses almost exclusively on promoting one product, highlighting its advantages while omitting limitations, contraindications, and alternative methods of treatment.</p>



<p id="ember116">In practice, it is worth adopting the principle that the more educational the material is, the greater the emphasis should be on presenting objective medical knowledge, and not only information beneficial to the manufacturer.</p>



<h2 class="wp-block-heading" id="ember117">Scientific conferences</h2>



<p id="ember118">Similar problems apply to industry conferences. Sponsorship of scientific events by medical device manufacturers is common practice and raises no objections in itself. However, risks arise when the scientific component is subordinated to marketing objectives.</p>



<p id="ember119">In practice, particular caution should be exercised when presenting research results for a specific product. Results should be presented honestly, taking into account methodological limitations and the full clinical context. Selectively presenting only favorable data may be viewed as misleading.</p>



<p id="ember120"><strong>LinkedIn – professional communication can also be advertising</strong></p>



<p id="ember121">Many content creators assume that since LinkedIn is primarily a professional platform, the content published there is strictly business-related. However, this assumption is far-fetched.</p>



<p id="ember122">If a LinkedIn entry is limited to information about participation in a conference, obtaining a certificate, a scientific publication or organizational changes in the company, it is generally difficult to attribute an advertising nature to it.</p>



<p id="ember123">However, if a publication contains incentives to use a specific product, comparisons with competitive products, promises of specific clinical effects or highlights the advantages of a product in order to increase sales, it may be considered advertising, regardless of the fact that it was published on a professional website.</p>



<p id="ember124">LinkedIn is increasingly being used as a marketing platform for the healthcare market. Therefore, communications conducted via this platform should also be subject to the company&#8217;s internal compliance procedures.</p>



<p id="ember125"><strong>Social media – the biggest challenge for the biostimulant market</strong></p>



<p id="ember126">Social media has completely transformed the way patients make decisions. Just a dozen or so years ago, the primary source of information was a doctor&#8217;s consultation and manufacturer-provided materials. Today, many patients primarily seek information on Instagram, TikTok, Facebook, and YouTube, guided by the opinions of influencers , physicians with educational profiles, and other users&#8217; testimonials.</p>



<p id="ember127">For entrepreneurs, this represents a huge marketing opportunity, but also significant regulatory risk. Traditional regulations regarding medical device advertising were designed with press, radio, and television advertising in mind. Modern online communication is much more dynamic and often combines elements of education, personal branding, and product promotion. As a result, assessing the legality of a specific message requires a case-by-case analysis of its actual purpose and context.</p>



<h2 class="wp-block-heading" id="ember128">Instagram – where does education end and advertising begin?</h2>



<p id="ember129">Instagram remains the most important communication channel used by aesthetic medicine clinics and physicians performing biostimulant treatments. This platform relies primarily on visual communication, which inherently has a stronger impact on audiences than traditional product descriptions.</p>



<p id="ember130">From a legal perspective, however, it cannot be assumed that every post about a procedure constitutes advertising. Physicians have the right to conduct educational activities, explain the mechanisms of individual procedures, discuss indications and contraindications, and comment on scientific publications. Such activities contribute to increasing patient awareness and should not, in and of themselves, be equated with advertising.</p>



<p id="ember131">The line is crossed when communication begins to focus on promoting a specific medical device or building its commercial appeal. This applies particularly to publications containing marketing slogans, incentives for procedures, information about price promotions, comparisons with competing products, or emphasizing the exceptional effectiveness of a specific product without providing the full medical context.</p>



<p id="ember132">In practice, it is worth adopting the rule that the more a post resembles advertising material prepared by a marketing agency, the greater the risk of it being classified as an advertisement for a medical device.</p>



<h2 class="wp-block-heading" id="ember133">TikTok – short form does not exempt from responsibility</h2>



<p id="ember134">Just a few years ago, few medical device manufacturers considered TikTok a business communication tool. Today, the situation is completely different. More and more clinics are publishing short videos demonstrating treatment procedures, patient reactions, and the aesthetic effects achieved after using specific products.</p>



<p id="ember135">The specific nature of this platform, however, means that the message is necessarily simplified. A video lasting several dozen seconds rarely allows for the presentation of contraindications, possible side effects, or limitations of the product&#8217;s use. As a result, there is an increased risk of creating a one-sided image of the product, highlighting only its benefits.</p>



<p id="ember136">From a compliance perspective , businesses should therefore exercise particular caution when preparing materials published on platforms based on short audiovisual forms. Merely shortening the message does not exempt them from ensuring its compliance with regulations on advertising medical devices.</p>



<h2 class="wp-block-heading" id="ember137">Influencer Marketing – New Regulatory Risk</h2>



<p id="ember138">influencers remains one of the most dynamically developing areas of marketing. This phenomenon has also impacted the aesthetic medicine market. Increasingly, individuals with significant social media followings are publishing treatment reports, presenting their recovery processes, and describing their own experiences using specific products.</p>



<p id="ember139">From a legal perspective, such collaboration requires special caution. Even if the influencer doesn&#8217;t mention a specific product, the way the treatment is presented can lead to increased interest in a specific technology or manufacturer. If the publication is created as part of a commercial collaboration, additional obligations arise under regulations regarding labeling advertising content and consumer protection.</p>



<p id="ember140">In practice, the producer should remember that responsibility for the legality of the message is not always limited solely to the influencer. Depending on the cooperation model, the entrepreneur initiating the campaign may also be responsible for the manner in which marketing communications are conducted.</p>



<p id="ember141"><strong>Doctor as a product ambassador</strong></p>



<p id="ember142">The use of physicians&#8217; authority to promote medical products remains a particularly sensitive issue. Public trust in medical professionals means their statements have a much greater impact than traditional advertising messages.</p>



<p id="ember143">This doesn&#8217;t mean, however, that doctors cannot publicly comment on the technologies they use. On the contrary, sharing medical knowledge, clinical experience, and research results is a crucial element in the development of medical science and practice. The problem arises only when a doctor&#8217;s statement ceases to be expert-based and begins to serve a marketing function.</p>



<p id="ember144">The risk increases especially when a physician appears in manufacturer-produced materials, uses promotional language, or explicitly encourages consumers to choose a specific product. In such cases, the regulatory authority may determine that the use of the medical profession&#8217;s authority serves to increase the product&#8217;s commercial appeal, which requires assessment from the perspective of regulations governing the advertising of medical devices.</p>



<h2 class="wp-block-heading" id="ember145">Before &#8211; after photos – an effective marketing tool or a source of risk?</h2>



<p id="ember146">One of the most distinctive elements of communication in aesthetic medicine is photographs depicting the patient&#8217;s appearance before and after the procedure. From a marketing perspective, this is an extremely effective tool for influencing potential clients. However, from a legal perspective, its use raises a number of concerns.</p>



<p id="ember147">Firstly, such materials often lead the recipient to believe that the treatment will provide a guaranteed result. However, the results of medical procedures depend on numerous individual factors, such as the patient&#8217;s health, age, biological predispositions, and adherence to post-treatment recommendations . Presenting single, spectacular results can lead to unrealistic expectations.</p>



<p id="ember148">Secondly, publishing patient photos requires compliance with regulations on personal data protection and the protection of personal rights. Consent to perform a procedure does not constitute consent to the dissemination of the image. The provider should obtain separate, informed, and voluntary consent covering the publication of photographs in specific communication channels.</p>



<p id="ember149">Third, it&#8217;s important to remember that even properly obtained patient consent doesn&#8217;t eliminate the risk of a publication being considered an advertisement for a medical device. If a photo is used to promote a specific product or increase interest in a specific procedure, the entire message should be assessed in light of advertising regulations.</p>



<p id="ember150">In practice, this means that the use of &#8221; before &#8211; after &#8221; photography requires simultaneous analysis from the perspective of medical device law, personal data protection, civil law, and consumer protection regulations. Failure to consider even one of these aspects can lead to significant legal risk.</p>



<h2 class="wp-block-heading" id="ember151">Misleading advertising – why can a truthful message also violate the law?</h2>



<p id="ember152">One of the most common mistakes made by businesses operating in the medical device market is the belief that because all information contained in an advertisement is truthful, the message is automatically legal. However, this assumption is far-fetched and is not supported by either the EU MDR or national regulations regarding medical device advertising.</p>



<p id="ember153">Assessing the legality of advertising is not limited to verifying the veracity of individual claims. Equally important are the manner in which they are presented, the context of the overall message, and the potential impact on the recipient&#8217;s decisions. Advertising can be misleading not only by providing false information, but also by selectively presenting facts, omitting important limitations, or emphasizing only the positive aspects of a product&#8217;s use.</p>



<p id="ember154">This is why Article 7 of the MDR should be considered one of the key regulations governing the marketing communications of medical device manufacturers. This provision prohibits the use of texts, names, trademarks, images, symbols, or other markings that could mislead the user or patient regarding the intended purpose, safety, or performance of the device. This prohibition applies not only to labels and instructions for use but also to advertising materials and other forms of market communication.</p>



<p id="ember155">In practice, this means that an entrepreneur should analyze each message not only in terms of compliance with the product&#8217;s technical documentation, but also from the perspective of how the average recipient might interpret the information presented.</p>



<p id="ember156"><strong>Not only falsehood, but also silence</strong></p>



<p id="ember157">One of the most frequently underestimated aspects of advertising is the responsibility for omitting information that is important to the recipient. Businesses typically focus on avoiding false claims, much less on analyzing the consequences of omitting specific information.</p>



<p id="ember158">Imagine an advertisement for a biostimulator in which the manufacturer presents excellent aesthetic results achieved after the treatment. All photographs are authentic, and the description of the effects reflects the actual experiences of selected patients. At the same time, the advertisement contains no information about the need for medical qualification, possible contraindications, the risk of side effects, or the body&#8217;s varied response to treatment.</p>



<p id="ember159">Formally, none of the claims presented are false. Nevertheless, the recipient may be misled into thinking that achieving the presented effect is typical, predictable, and practically guaranteed. Consequently, the message may be considered misleading because it creates unrealistic expectations regarding the product&#8217;s performance.</p>



<p id="ember160">A similar risk arises when using terms such as &#8220;safe,&#8221; &#8220;non-invasive,&#8221; &#8220;natural,&#8221; or &#8220;side-effect-free.&#8221; Even if a product has a high safety profile, using such phrases can imply an absence of risk, which is difficult to reconcile with clinical reality.</p>



<h2 class="wp-block-heading" id="ember161">Can we use the terms “best”, “most effective” or “revolutionary”?</h2>



<p id="ember162">Marketing language often relies on the use of evaluative terms. Advertisements feature phrases such as &#8220;market leader,&#8221; &#8220;the most innovative product,&#8221; &#8220;the best rejuvenation technology,&#8221; or &#8220;a breakthrough in aesthetic medicine.&#8221; In the consumer goods sector, this type of communication is common. However, when it comes to medical devices, much greater caution is required.</p>



<p id="ember163">First, an entrepreneur should have objective evidence to support any comparative or evaluative claim. Second, even the existence of scientific research does not always justify the use of terms suggesting absolute superiority over all competing solutions. In medical practice, the effectiveness of therapy depends on many factors, including the patient&#8217;s qualifications, the physician&#8217;s experience, and individual biological conditions.</p>



<p id="ember164">From a compliance perspective, a much safer solution is to use a description based on clinical trial results and technical parameters of the product, instead of using general marketing slogans.</p>



<p id="ember165"><strong>Practice of supervisory authorities – the growing importance of digital communication</strong></p>



<p id="ember166">Recent years have seen a significant increase in supervisory authorities&#8217; interest in online communications. While previously, oversight activities focused primarily on traditional advertising materials, they now also analyze websites, social media profiles, newsletters, videos published on streaming platforms , and collaborations with influencers.</p>



<p id="ember167">This trend is consistent with a broader trend observed at the EU level, where increasing emphasis is being placed on countering manipulative marketing practices and ensuring a high level of protection for consumers using healthcare services. Consequently, businesses should assume that online communications are subject to the same scrutiny as traditional forms of advertising.</p>



<h2 class="wp-block-heading" id="ember168">The Polish Office of Competition and Consumer Protection and consumer protection – the second pillar of responsibility</h2>



<p id="ember169">Although the primary legislation regulating the advertising of medical devices remains the Medical Devices Act, businesses cannot limit their analysis solely to this legal regime. Consumer protection regulations also apply, in particular the Act on Combating Unfair Market Practices and the Act on Competition and Consumer Protection.</p>



<p id="ember170">From the perspective of the President of the Office of Competition and Consumer Protection (UOKiK), the impact of a message on the average consumer is of particular importance. If a communication exploits emotions, raises unjustified expectations, or suggests characteristics that the recipient is unable to independently verify, it may be considered a practice that violates the collective interests of consumers.</p>



<p id="ember171">In practice, this means that a single marketing campaign may be assessed simultaneously by different authorities under different legal frameworks. Manufacturers should therefore design their marketing activities to ensure compliance not only with medical device regulations but also with consumer protection and fair competition regulations.</p>



<p id="ember172"><strong>Compliance instead of reaction after inspection</strong></p>



<p id="ember173">Experience in recent years shows that a significant number of violations are not the result of deliberate actions by businesses, but rather a lack of appropriate internal procedures. Marketing materials are often prepared by external advertising agencies that are intimately familiar with the mechanisms of selling consumer products but lack experience in the regulated sector.</p>



<p id="ember174">compliance systems that encompass the entire marketing communications process is becoming increasingly important . Every piece of content &#8211; whether it&#8217;s an Instagram post, a product brochure, a webinar , or a YouTube video &#8211; should be reviewed not only by the marketing department but also by those responsible for regulatory and legal matters.</p>



<p id="ember175">This approach allows for the identification of risks before the material is published, reducing the likelihood of initiating administrative proceedings, disputes with supervisory authorities and negative image consequences.</p>



<h2 class="wp-block-heading" id="ember176">The most common mistakes of manufacturers, importers, distributors and clinics – what to avoid in practice?</h2>



<p id="ember177">Recent experience shows that most violations of regulations regarding medical device advertising do not result from deliberate disregard for applicable regulations. Quite the opposite – entrepreneurs operating in the aesthetic medicine market typically strive to conduct their business in compliance with the law, but they encounter difficulties resulting from ambiguous regulations and the dynamic development of modern communication channels. Marketing of medical products is increasingly conducted via social media, educational platforms, and industry events, whereas existing regulations were primarily designed with traditional forms of advertising in mind.</p>



<p id="ember178">In practice, however, there are several recurring mistakes that occur regardless of the size of the company and which should be taken into account when designing a marketing strategy.</p>



<p id="ember179"><strong>Mistake No. 1 – Equating commercial information with neutral information</strong></p>



<p id="ember180">One of the most common misconceptions is that material doesn&#8217;t constitute advertising solely because a business owner has designated it as &#8220;information.&#8221; This approach is unsupported by applicable law.</p>



<p id="ember181">The nature of a message is assessed based on its actual function, not the name given by the author. If the material highlights the benefits of a specific product, builds its market appeal, or is intended to encourage the recipient to choose a specific product, there is a high probability that it will be classified as an advertisement, even if it does not contain a classic call to purchase.</p>



<p id="ember182">An example would be an article published on the manufacturer&#8217;s website titled &#8220;Modern Skin Regeneration Possibilities.&#8221; If the majority of the text is devoted to a single product, highlights its advantages over the competition, and leads to a contact form allowing purchase of the product or registration for training, it&#8217;s difficult to consider such material solely educational.</p>



<p id="ember183">In practice, entrepreneurs should remember that supervisory authorities analyze not only the content of the publication, but also its location, method of presentation and connection with the entrepreneur&#8217;s business activity.</p>



<p id="ember184"><strong>Mistake #2 – Copying Cosmetic Product Marketing</strong></p>



<p id="ember185">The aesthetic medicine market is developing in parallel with the cosmetics market, resulting in many marketing activities being mutually inspired. However, from a regulatory perspective, this approach can lead to serious problems.</p>



<p id="ember186">Cosmetics marketing relies primarily on building emotions, visual appeal, and creating a specific lifestyle. Meanwhile, communication regarding medical devices is subject to much more stringent requirements. Using identical marketing techniques for products covered by the MDR may lead to violations of advertising regulations, especially if the message ignores the limitations imposed by the product&#8217;s intended use or its method of use.</p>



<p id="ember187">In practice, this means that the marketing department of a medical device manufacturer should not automatically use solutions used in cosmetic campaigns, even if they seem effective from a business point of view.</p>



<p id="ember188"><strong>Mistake No. 3 – overexposing the effects of the treatment</strong></p>



<p id="ember189">Marketing materials for biostimulants often focus almost exclusively on aesthetic effects. Images depicting wrinkle smoothing, facial contour improvement, or increased skin firmness undoubtedly attract audiences and enhance the message&#8217;s appeal.</p>



<p id="ember190">The problem, however, is that the results of aesthetic medicine treatments are individual. They depend on the patient&#8217;s age, health, skin condition, previous medical procedures, lifestyle, and the experience of the practitioner. Presenting individual, exceptionally positive results without proper context can lead to unrealistic expectations on the part of potential patients.</p>



<p id="ember191">From a compliance perspective , it is much safer to present information about the mechanism of action of the product and its intended use than to focus all communication on spectacular visual effects.</p>



<p id="ember192"><strong>Mistake No. 4 – Ignoring contraindications and limitations of use</strong></p>



<p id="ember193">Another common mistake is presenting a product solely through the lens of its benefits. Marketing materials often emphasize the product&#8217;s effectiveness, innovation, and safety, while failing to mention situations in which its use may be inadvisable.</p>



<p id="ember194">Meanwhile, reliable communication regarding medical devices should also include information about contraindications, limitations of use, and the need for medical qualification. This doesn&#8217;t mean, of course, that every advertisement must include full instructions for use, but omitting all information regarding potential risks could lead to accusations of misleading consumers.</p>



<p id="ember195"><strong>Mistake #5 – Lack of cooperation between marketing and legal departments</strong></p>



<p id="ember196">In many companies, marketing materials are prepared by external creative agencies or marketing departments that lack specialized knowledge of medical device regulations. Only then does the completed material reach the legal department, often just prior to publication.</p>



<p id="ember197">affairs specialists and lawyers at the marketing campaign design stage. This avoids the need for later material withdrawal or costly modification.</p>



<p id="ember198"><strong>Mistake #6 – Lack of social media procedures</strong></p>



<p id="ember199">Many companies have extensive procedures for approving product catalogs and printed materials, yet they don&#8217;t regulate the rules for publishing content on social media. Yet, it&#8217;s short posts on Instagram, Facebook, and LinkedIn that are currently published most frequently and have the greatest impact on a company&#8217;s image.</p>



<p id="ember200">The lack of internal guidelines leads individual employees to publish content at their own discretion, often unaware of the legal consequences of using specific phrases or photographs. In practice, it&#8217;s worth developing separate policies for online communication, covering topics such as product presentation, use of photographic materials, publishing coverage of industry events, and collaborating with physicians and influencers.</p>



<p id="ember201"><strong>Compliance practices – how to organize legal marketing communications?</strong></p>



<p id="ember202">Compliance system shouldn&#8217;t be limited to merely responding to emerging issues. Its primary goal is to prevent violations by establishing transparent rules for preparing and approving marketing materials.</p>



<p id="ember203">In practice, a growing number of medical device manufacturers are implementing multi-stage approval procedures involving marketing departments, regulatory affairs specialists, quality control departments, and lawyers. This model allows for the assessment of a material not only in terms of its marketing appeal but also its compliance with the product&#8217;s technical documentation, instructions for use, and applicable regulations.</p>



<p id="ember204">Maintaining documentation of the approval process is also particularly important. In the event of an audit, the company should be able to demonstrate that the materials were prepared in accordance with internal procedures and reviewed by appropriately qualified individuals. Archiving subsequent versions of materials, legal opinions, and publication decisions can be of significant evidentiary value.</p>



<p id="ember205">In practice, a well-functioning compliance system shouldn&#8217;t be perceived as an obstacle to marketing activities. On the contrary, properly designed procedures enable legally secure communication, reducing the risk of administrative sanctions and disputes with supervisory authorities, while building trust with customers and business partners.</p>



<p id="ember206"><strong>European perspective – why will the importance of compliance systematically grow?</strong></p>



<p id="ember207">Polish regulations on medical device advertising are currently among the most detailed in the European Union. However, this does not mean that businesses operating in the domestic market can limit themselves solely to knowledge of the provisions of the Medical Devices Act and the Regulation of the Minister of Health. The functioning of the medical devices market is increasingly determined by the practice of applying the MDR, the positions of EU bodies, and the actions of national regulatory authorities in individual member states.</p>



<p id="ember208">The MDR does not contain comprehensive regulations on the advertising of medical devices. It focuses primarily on product safety, manufacturers&#8217; obligations, conformity assessment, and the rules for placing devices on the market. At the same time, Article 7 of the MDR establishes the general principle that all communication about a device – regardless of its form – must not mislead users or patients about the product&#8217;s intended purpose, properties, safety, or efficacy.</p>



<p id="ember209">In practice, this provision serves a much broader purpose than the classic ban on misleading advertising. It constitutes a specific interpretative principle that should be considered when assessing every form of communication conducted by a manufacturer or distributor. Increasingly, supervisory authorities are moving away from formalistic analysis of individual advertising slogans and focusing on the overall perception of the message by the average user.</p>



<p id="ember210">At the same time, the activities of <strong>Medical Device Coordination Group (MDCG) </strong>highlights the growing importance of transparent information provided to users of medical devices. Although MDCG documents are not legally binding, in practice they guide the interpretation of MDR provisions by national authorities and notified bodies. Increasing emphasis is being placed on ensuring consistency between a device&#8217;s technical documentation, instructions for use, and market communications.</p>



<p id="ember211">It can be predicted that in the coming years, marketing control will encompass not only traditional advertising but also recommendation algorithms of online platforms, message personalization, the use of artificial intelligence in marketing, and automated advertising profiles. The development of new technologies is blurring the lines between information, advertising, and educational content.</p>



<p id="ember212">For manufacturers, this means moving away from a one-time approach to assessing marketing materials. Implementing ongoing compliance procedures that enable ongoing assessment of communications&#8217; compliance with rapidly evolving regulatory requirements will be much more effective.</p>



<h2 class="wp-block-heading" id="ember213">Practical checklist compliance before publishing marketing materials</h2>



<p id="ember214">In practice, most violations can be avoided by implementing simple verification procedures. Before publishing material regarding a medical device, it&#8217;s important to answer the following questions:</p>



<p id="ember215"><strong>First</strong>, is the product intended for use by laypeople or exclusively by professionals? The answer to this question determines the acceptable scope of communication and the target audience.</p>



<p id="ember216"><strong>Secondly</strong>, is the planned material truly informative, or is its primary purpose to increase interest in the product? When in doubt, it&#8217;s worth adopting a more cautious approach and evaluating the message according to advertising principles.</p>



<p id="ember217"><strong>Third</strong>, are all claims regarding product properties supported by technical documentation, instructions for use, and conformity assessment results? Marketing departments should not independently make new claims regarding product effectiveness or safety.</p>



<p id="ember218"><strong>Fourthly</strong>, does the material use evaluative terms such as &#8220;best&#8221;, &#8220;most effective&#8221;, &#8220;revolutionary&#8221; or &#8220;guaranteed effect&#8221;, the validity of which could be questioned by the supervisory authority?</p>



<p id="ember219"><strong>Fifth</strong>, does the message include product use restrictions, the need for medical qualification, and other information relevant to user safety?</p>



<p id="ember220"><strong>Sixth</strong>, does the publication contain photographs or recordings of patients? If so, it is necessary to verify not only compliance with regulations on advertising medical devices, but also the basis for processing personal data, the scope of consent granted, and the protection of personal rights.</p>



<p id="ember221"><strong>Seventh</strong>, was the material reviewed by those responsible for regulatory and legal matters? In practice, even minor linguistic changes can significantly alter the legal assessment of the entire message.</p>



<p id="ember222"><strong>Eighth</strong>, does the entrepreneur have documentation confirming the material approval process? In the event of an audit, the ability to demonstrate organizational diligence can be crucial to assessing the entrepreneur&#8217;s actions.</p>



<h2 class="wp-block-heading" id="ember223">Summary</h2>



<p id="ember224">The development of the biostimulator market is one of the most dynamic areas in contemporary aesthetic medicine. These products respond to growing patient expectations for natural tissue regeneration methods, while simultaneously posing entirely new regulatory challenges for manufacturers, importers, distributors, and healthcare providers.</p>



<p id="ember225">Contrary to popular belief, the biggest problem today isn&#8217;t the mere ability to advertise. The key challenge remains the ability to communicate effectively, while simultaneously providing accurate product information and complying with stringent legal requirements. The line between information and advertising is becoming increasingly blurred, especially in the digital environment, where communication occurs via social media, educational platforms, and artificial intelligence tools.</p>



<p id="ember226">From the perspective of entrepreneurs, this means a shift in thinking about medical device marketing. Instead of treating compliance as a final stage of reviewing advertising materials, it&#8217;s worth viewing them as an integral element of the process of designing market communication. Early involvement of legal, regulatory, and quality specialists not only reduces the risk of administrative sanctions but also builds brand credibility and audience trust.</p>



<p id="ember227">It can be expected that the requirements for communication transparency will systematically increase in the coming years. The development of artificial intelligence, data-driven marketing, and message personalization will force supervisory authorities to increasingly scrutinize not only the content of advertisements but also their distribution and impact on audience decisions. In this environment, competitive advantage will be achieved not by those businesses that conduct the most aggressive marketing communications, but by those that manage to combine innovation with regulatory responsibility.</p>
<p> </p>
<p>Artykuł <a href="https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/biostimulants-under-the-microscope-of-the-law-where-does-information-end-and-prohibited-advertising-of-medical-devices-begin/">Biostimulants under the microscope of the law – where does information end and prohibited advertising of medical devices begin?</a> pochodzi z serwisu <a href="https://www.kg-legal.eu">KIELTYKA GLADKOWSKI LEGAL | CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/biostimulants-under-the-microscope-of-the-law-where-does-information-end-and-prohibited-advertising-of-medical-devices-begin/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>CLIENT ALERT Dietary supplements market in Poland Amendments to food safety regulations &#124; May 2026</title>
		<link>https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/client-alert-dietary-supplements-market-in-polandamendments-to-food-safety-regulations-may-2026/</link>
					<comments>https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/client-alert-dietary-supplements-market-in-polandamendments-to-food-safety-regulations-may-2026/#respond</comments>
		
		<dc:creator><![CDATA[jakub]]></dc:creator>
		<pubDate>Wed, 08 Jul 2026 11:04:24 +0000</pubDate>
				<category><![CDATA[PHARMACEUTICAL, HEALTHCARE & LIFE SCIENCES LAW]]></category>
		<category><![CDATA[Advertising Law]]></category>
		<category><![CDATA[Business Law]]></category>
		<category><![CDATA[CEE]]></category>
		<category><![CDATA[Central and Eastern Europe]]></category>
		<category><![CDATA[Client Alert]]></category>
		<category><![CDATA[Commercial Law]]></category>
		<category><![CDATA[Compliance Management]]></category>
		<category><![CDATA[Consumer Health]]></category>
		<category><![CDATA[CONSUMER PROTECTION]]></category>
		<category><![CDATA[Corporate Compliance]]></category>
		<category><![CDATA[corporate law]]></category>
		<category><![CDATA[Cross-Border Business]]></category>
		<category><![CDATA[Dietary Supplements]]></category>
		<category><![CDATA[Distributors]]></category>
		<category><![CDATA[Doing business in Poland]]></category>
		<category><![CDATA[e-commerce]]></category>
		<category><![CDATA[e-Sanepid]]></category>
		<category><![CDATA[EU Law]]></category>
		<category><![CDATA[European Regulatory Law]]></category>
		<category><![CDATA[European Union Law]]></category>
		<category><![CDATA[Food and Nutrition Safety Act]]></category>
		<category><![CDATA[Food Business]]></category>
		<category><![CDATA[food industry]]></category>
		<category><![CDATA[Food Law]]></category>
		<category><![CDATA[Food Regulation]]></category>
		<category><![CDATA[Food Safety]]></category>
		<category><![CDATA[Food Supplements]]></category>
		<category><![CDATA[General Counsel]]></category>
		<category><![CDATA[GIS]]></category>
		<category><![CDATA[Healthcare Law]]></category>
		<category><![CDATA[Importers]]></category>
		<category><![CDATA[In-House Counsel]]></category>
		<category><![CDATA[International Business]]></category>
		<category><![CDATA[International Lawyers]]></category>
		<category><![CDATA[international trade]]></category>
		<category><![CDATA[KG Legal]]></category>
		<category><![CDATA[kiełtyka gładkowski]]></category>
		<category><![CDATA[Law Firm]]></category>
		<category><![CDATA[Legal Compliance]]></category>
		<category><![CDATA[Legal Insights]]></category>
		<category><![CDATA[Legal Risk]]></category>
		<category><![CDATA[Legal Update]]></category>
		<category><![CDATA[Life Sciences]]></category>
		<category><![CDATA[Manufacturers]]></category>
		<category><![CDATA[Market Entry]]></category>
		<category><![CDATA[Nutraceuticals]]></category>
		<category><![CDATA[Online Retail]]></category>
		<category><![CDATA[Poland]]></category>
		<category><![CDATA[Poland Food Law]]></category>
		<category><![CDATA[Polish Food Law]]></category>
		<category><![CDATA[Product Compliance]]></category>
		<category><![CDATA[Product Safety]]></category>
		<category><![CDATA[Regulatory Affairs]]></category>
		<category><![CDATA[Regulatory Compliance]]></category>
		<category><![CDATA[Regulatory Law]]></category>
		<category><![CDATA[Risk Management]]></category>
		<guid isPermaLink="false">https://www.kg-legal.eu/?p=8825</guid>

					<description><![CDATA[<p>Publication date: July 07, 2026 The draft Act of April 13, 2026, amending the Act on Food and Nutrition Safety will enter into force six months after its publication. The new regulations primarily impact producers, importers, distributors, and sellers of dietary supplements &#8211; both in traditional and online channels. Below, we present the real changes [&#8230;]</p>
<p>Artykuł <a href="https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/client-alert-dietary-supplements-market-in-polandamendments-to-food-safety-regulations-may-2026/">CLIENT ALERT Dietary supplements market in Poland Amendments to food safety regulations | May 2026</a> pochodzi z serwisu <a href="https://www.kg-legal.eu">KIELTYKA GLADKOWSKI LEGAL | CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p><strong><mark style="background-color:rgba(0, 0, 0, 0)" class="has-inline-color has-vivid-cyan-blue-color">Publication date: July 07, 2026</mark></strong></p>



<figure class="wp-block-table"><table class="has-fixed-layout"><tbody><tr><td><em>The draft Act of April 13, 2026, amending the Act on Food and Nutrition Safety will enter into force six months after its publication. The new regulations primarily impact producers, importers, distributors, and sellers of dietary supplements &#8211; both in traditional and online channels. Below, we present the real changes to your business.</em></td></tr></tbody></table></figure>



<span id="more-8825"></span>



<h1 class="wp-block-heading">1. Reports only via e-Sanepid</h1>



<p>Every dietary supplement introduced to the market for the first time must be reported to the Chief Sanitary Inspector (GIS). Until now, various forms were acceptable &#8211; paper or electronic, with a handwritten or electronic signature. After the amendment comes into effect, the only acceptable method will be the e-Sanepid platform.</p>



<p>What does this mean in practice?</p>



<ul class="wp-block-list">
<li>It is necessary for each person submitting notifications to have a qualified electronic signature or a trusted profile.</li>



<li>All communication with sanitary inspection bodies &#8211; letters, decisions, and confirmations &#8211; will be handled through the platform account. The moment of notification submission will be clearly confirmed with an official receipt, eliminating disputes over the deadline.</li>



<li>Companies that have previously used paper forms or traditional correspondence must immediately switch to the new channel and ensure appropriate employee training.</li>
</ul>



<p>The change also concerns the timing of the notification obligation: the previous option to notify the Chief Sanitary Inspectorate (GIS) at the stage of intended product introduction is no longer available. The obligation now arises at the time of actual introduction to the market.</p>



<h1 class="wp-block-heading">2. Strict deadlines and automatic presumption of irregularities</h1>



<p>The amendment introduces a completely new mechanism for conducting investigations. This change has the greatest potential to surprise companies without effective internal compliance procedures.</p>



<h2 class="wp-block-heading">How does the new mechanism work?</h2>



<p>If the Chief Sanitary Inspectorate initiates an investigation and requests the entity to submit a scientific opinion, the company has exactly 14 days to submit an application to an accredited scientific unit – at the same time forwarding a copy of it to the Chief Sanitary Inspectorate.</p>



<figure class="wp-block-table"><table class="has-vivid-cyan-blue-color has-luminous-vivid-amber-background-color has-text-color has-background has-link-color has-fixed-layout"><tbody><tr><td><strong>Step</strong></td><td><strong>What&#8217;s going on</strong></td></tr><tr><td><strong>14 days</strong></td><td>Deadline for submitting an application for a scientific opinion to a scientific unit (from the date of delivery of the request by GIS)</td></tr><tr><td><strong>6 months</strong></td><td>Maximum time for a scientific unit to issue an opinion</td></tr><tr><td><strong>Up to 12 months</strong></td><td>Possible extension of the deadline by the entity if the case is complex</td></tr><tr><td><strong>Failure to meet 14 days</strong></td><td>Automatic presumption that the product is incorrectly classified and does not meet the requirements &#8211; GIS ends the proceedings to the detriment of the entity</td></tr></tbody></table></figure>



<p>The mechanism for presuming irregularities is a significant innovation. Previously, a company&#8217;s inaction during the proceedings did not automatically result in any legal consequences &#8211; the proceedings could drag on for years. Following the amendment, any failure to meet the 14-day deadline will lead to direct negative consequences, regardless of whether the product is safe.</p>



<figure class="wp-block-table"><table class="has-fixed-layout"><tbody><tr><td><strong>The ban on re-registration – an important trap</strong></td></tr><tr><td>Once the investigation is complete, the entity cannot submit a new notification for a product with the same qualitative and quantitative composition. If the company withdraws its notification during the investigation, this prohibition is indefinite. In such cases, changing the composition may be the only way to return to the market.</td></tr></tbody></table></figure>



<h1 class="wp-block-heading">3. Advertising without reporting? A fine of nearly one million zlotys</h1>



<p>This change directly impacts brands engaging in active digital marketing. Previously, advertising or presenting a dietary supplement without prior notification to the Chief Sanitary Inspectorate (GIS) was punishable by a fine (a misdemeanor). Following the amendment, this becomes grounds for imposing an administrative fine &#8211; with new, significantly higher penalties.</p>



<h2 class="wp-block-heading">What exactly is prohibited?</h2>



<p>The amendment penalizes not only the sale of a supplement without reporting it to the Chief Sanitary Inspectorate (GIS), but also the mere advertising or presentation of it if the notification has not been effectively submitted. In other words:</p>



<ul class="wp-block-list">
<li>Sponsored post on Instagram or Facebook promoting a new supplement before notification = grounds for an administrative penalty.</li>



<li>Product page in the online store visible to the public before successful reporting to GIS = risk of infringement.</li>



<li>Promotional materials sent to wholesalers or distributors before GIS is notified = potential infringement.</li>



<li>Influencer marketing initiated before the date of effective notification = liability on the part of the entity commissioning the campaign.</li>
</ul>



<figure class="wp-block-table"><table class="has-fixed-layout"><tbody><tr><td><strong>Key: What is a &#8220;successful report&#8221;?</strong></td></tr><tr><td>The notification is effectively submitted when the company receives official confirmation of receipt from the e-Sanepid platform. Simply submitting the form isn&#8217;t enough &#8211; confirmation is what counts. These dates can differ by several days or more. Every marketing campaign should be planned with this time buffer in mind.</td></tr></tbody></table></figure>



<h2 class="wp-block-heading">Prohibition on suggesting medicinal properties &#8211; wider scope</h2>



<p>The amendment expands liability for violations of advertising requirements from labeling to the entire marketing message. Previously, sanctions primarily covered incorrect packaging labeling. Following the amendment, a company is responsible for every communication channel &#8211; online advertising, point-of-sale materials, newsletters, or YouTube videos &#8211; if the message suggests that a varied diet does not provide sufficient nutrients, or if a supplement is presented as a medicinal product.</p>



<h1 class="wp-block-heading">4. Public register &#8211; the company&#8217;s reputation under public scrutiny</h1>



<p>The Chief Sanitary Inspectorate (GIS) has maintained a register of dietary supplements before, but the amendment will significantly expand its scope and availability. The data will be published on the e-Sanepid platform and will include:</p>



<ul class="wp-block-list">
<li>the name of the product and its qualitative composition (without quantitative data &#8211; the recipe remains protected),</li>



<li>product qualification proposed by the entity,</li>



<li>information about the initiation or ongoing investigation,</li>



<li>data on the detection of a prohibited ingredient.</li>
</ul>



<figure class="wp-block-table"><table class="has-fixed-layout"><tbody><tr><td><strong>Reputational risk before final decision</strong></td></tr><tr><td>Information about the initiation of an investigation will appear in the public register immediately &#8211; not after the proceedings have concluded. Consumers and competitors will have access to this information before the Chief Sanitary Inspectorate issues any ruling. Even if the proceedings end favorably for the company, the registry record could impact brand perception.</td></tr></tbody></table></figure>



<h1 class="wp-block-heading">5. Fines &#8211; increase by over 330%</h1>



<p>The maximum administrative fine for violating food safety regulations is increasing from 30 to 100 times the average monthly salary. At the current salary level, this means:</p>



<figure class="wp-block-table"><table class="has-fixed-layout"><tbody><tr><td>&nbsp;</td><td><strong>Before the amendment</strong></td><td><strong>After the amendment</strong></td></tr><tr><td><strong>Multiplier</strong></td><td>30×</td><td><strong>100×</strong></td></tr><tr><td><strong>Maximum penalty</strong></td><td>approx. PLN 245,000</td><td><strong>approx. PLN 818,000</strong></td></tr></tbody></table></figure>



<p>The new penalties are imposed administratively (not as fiscal or misdemeanor offenses), which means faster proceedings and no need to prove intentional guilt. A mere finding of a violation is sufficient. The increased level of sanctions has a real deterrent effect, especially for companies with turnover in the tens of millions of zlotys.</p>



<h1 class="wp-block-heading">The biggest risks &#8211; a practical overview</h1>



<figure class="wp-block-table"><table class="has-fixed-layout"><tbody><tr><td><strong>Risk area</strong></td><td><strong>Triggering situation</strong></td><td><strong>Consequence</strong></td></tr><tr><td><strong>Advertising before submission</strong></td><td>Launch of the campaign on social media before the official confirmation of receipt of the notification by the Chief Sanitary Inspectorate</td><td>Fine up to approximately PLN 818,000</td></tr><tr><td><strong>Exceeding the 14-day deadline</strong></td><td>No application submitted to the scientific unit within 14 days of the request by the Chief Sanitary Inspectorate</td><td>Automatic presumption of product irregularity; termination of proceedings to the detriment of the entity</td></tr><tr><td><strong>Errors in the product description on the website</strong></td><td>Content suggesting medicinal properties or claiming that a diet without a supplement is insufficient</td><td>Fine of up to approximately PLN 818,000; risk of product recall</td></tr><tr><td><strong>Publicity of the proceedings</strong></td><td>Initiation of explanatory proceedings by GIS</td><td>Immediate publication of information in the public register &#8211; reputational damage before resolution</td></tr><tr><td><strong>Sale without notification</strong></td><td>Distribution to wholesalers or stores before effective notification of the Chief Sanitary Inspectorate</td><td>A fine of up to approximately PLN 818,000; possible ban on further trading</td></tr><tr><td><strong>No trusted profile/signature</strong></td><td>The employees responsible for reporting do not have the required qualifications</td><td>Notification submitted ineffectively &#8211; risk of sanctions as for failure to notify</td></tr></tbody></table></figure>



<figure class="wp-block-table"><table class="has-fixed-layout"><tbody><tr><td><strong>What is worth doing before the regulations come into force?</strong></td></tr></tbody></table></figure>



<figure class="wp-block-table"><table class="has-fixed-layout"><tbody><tr><td><strong>1. Register on the e-Sanepid platform</strong></td></tr><tr><td>Ensure that at least two people in your company have a qualified electronic signature or an active trusted profile. Register a company account on e-Sanepid before the law comes into effect and complete a test application. A lack of technical readiness on the date the regulations come into effect could prevent you from legally introducing new products to the market.</td></tr></tbody></table></figure>



<figure class="wp-block-table"><table class="has-fixed-layout"><tbody><tr><td><strong>2. Audit current submissions and the new product calendar</strong></td></tr><tr><td>Check that all products in your offer have successfully submitted notifications to the Chief Sanitary Inspectorate. For products planned for launch in the coming months, submit notifications well in advance of the planned sale date or marketing campaign. Take into account the waiting time for official confirmation of receipt.</td></tr></tbody></table></figure>



<figure class="wp-block-table"><table class="has-fixed-layout"><tbody><tr><td><strong>3. Implement a procedure for monitoring deadlines in explanatory proceedings</strong></td></tr><tr><td>Designate a person responsible for receiving correspondence from the e-Sanepid platform and immediately forwarding documents to legal or compliance services. The 14-day deadline for submitting a request for a scientific opinion is short—missing it automatically creates a presumption of irregularities. It&#8217;s worth identifying accredited scientific institutions now with which the company could quickly establish cooperation if proceedings are initiated.</td></tr></tbody></table></figure>



<figure class="wp-block-table"><table class="has-fixed-layout"><tbody><tr><td><strong>4. Verify all marketing materials – websites, social media, product descriptions</strong></td></tr><tr><td>Analyze the content on your website, online store, social media profiles and sales materials for:</td></tr><tr><td>suggestions for medicinal or therapeutic properties of supplements,</td></tr><tr><td>information suggesting that a normal diet does not provide adequate nutrients,</td></tr><tr><td>promoting products for which the GIS notification has not yet been successfully submitted.</td></tr><tr><td>Influencer marketing campaigns deserve special attention – messages created by third parties still place the responsibility on the company commissioning the campaign.</td></tr></tbody></table></figure>



<figure class="wp-block-table">
<table class="has-fixed-layout">
<tbody>
<tr>
<td><strong>5. Monitor the GIS register and respond to information about proceedings</strong></td>
</tr>
<tr>
<td>Once the expanded SEPIS register is launched, regularly check the status of your products. If you receive information about the initiation of an investigation, act immediately. Inaction at this stage can lead to automatic assumptions of irregularities and reputational damage that will be publicly visible throughout the proceedings.</td>
</tr>
</tbody>
</table>
</figure>
<p> </p>
<p>Artykuł <a href="https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/client-alert-dietary-supplements-market-in-polandamendments-to-food-safety-regulations-may-2026/">CLIENT ALERT Dietary supplements market in Poland Amendments to food safety regulations | May 2026</a> pochodzi z serwisu <a href="https://www.kg-legal.eu">KIELTYKA GLADKOWSKI LEGAL | CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/client-alert-dietary-supplements-market-in-polandamendments-to-food-safety-regulations-may-2026/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>A Major Milestone for KG Legal&#8217;s Data, AI &#038; Cybersecurity Practice: Exclusive Poland Contribution to OneTrust DataGuidance</title>
		<link>https://www.kg-legal.eu/info/kg-legal-news/a-major-milestone-for-kg-legals-data-ai-cybersecurity-practice-exclusive-poland-contribution-to-onetrust-dataguidance/</link>
					<comments>https://www.kg-legal.eu/info/kg-legal-news/a-major-milestone-for-kg-legals-data-ai-cybersecurity-practice-exclusive-poland-contribution-to-onetrust-dataguidance/#respond</comments>
		
		<dc:creator><![CDATA[jakub]]></dc:creator>
		<pubDate>Tue, 07 Jul 2026 19:32:01 +0000</pubDate>
				<category><![CDATA[KG LEGAL NEWS]]></category>
		<category><![CDATA[AI Act]]></category>
		<category><![CDATA[AI Compliance]]></category>
		<category><![CDATA[AI Regulation]]></category>
		<category><![CDATA[Artificial intelligence]]></category>
		<category><![CDATA[CEE]]></category>
		<category><![CDATA[Corporate Counsel]]></category>
		<category><![CDATA[Cross Border Business]]></category>
		<category><![CDATA[Cross Border Legal Services]]></category>
		<category><![CDATA[Cyber Compliance]]></category>
		<category><![CDATA[Cyber Law]]></category>
		<category><![CDATA[Data Governance]]></category>
		<category><![CDATA[Data Privacy]]></category>
		<category><![CDATA[data protection]]></category>
		<category><![CDATA[DataGuidance]]></category>
		<category><![CDATA[Digital Compliance]]></category>
		<category><![CDATA[Digital Economy]]></category>
		<category><![CDATA[Digital Law]]></category>
		<category><![CDATA[Doing business in Poland]]></category>
		<category><![CDATA[Emerging Technologies]]></category>
		<category><![CDATA[EU Law]]></category>
		<category><![CDATA[European Law]]></category>
		<category><![CDATA[Foreign Investors]]></category>
		<category><![CDATA[gdpr]]></category>
		<category><![CDATA[GDPR Compliance]]></category>
		<category><![CDATA[GDPR Poland]]></category>
		<category><![CDATA[General Counsel]]></category>
		<category><![CDATA[Global Law]]></category>
		<category><![CDATA[Healthcare Law]]></category>
		<category><![CDATA[Healthcare Regulation]]></category>
		<category><![CDATA[In House Counsel]]></category>
		<category><![CDATA[International Law Firm]]></category>
		<category><![CDATA[International Legal Services]]></category>
		<category><![CDATA[Invest in Poland]]></category>
		<category><![CDATA[kglegal]]></category>
		<category><![CDATA[kiełtyka gładkowski]]></category>
		<category><![CDATA[Law Firm Poland]]></category>
		<category><![CDATA[Legal Innovation]]></category>
		<category><![CDATA[Legal Tech]]></category>
		<category><![CDATA[Legal Thought Leadership]]></category>
		<category><![CDATA[Life Sciences Law]]></category>
		<category><![CDATA[NIS2]]></category>
		<category><![CDATA[OneTrust]]></category>
		<category><![CDATA[Pharmaceutical Law]]></category>
		<category><![CDATA[Poland Law]]></category>
		<category><![CDATA[Polish law]]></category>
		<category><![CDATA[Polish Law Firm]]></category>
		<category><![CDATA[Privacy Law]]></category>
		<category><![CDATA[Regulatory Compliance]]></category>
		<category><![CDATA[Technology Law]]></category>
		<category><![CDATA[Technology Transactions]]></category>
		<guid isPermaLink="false">https://www.kg-legal.eu/?p=8822</guid>

					<description><![CDATA[<p>Publication date: July 07, 2026 We are delighted to share an important milestone in the continued development of KG Legal&#8217;s Data, AI &#38; Cybersecurity Desk. It has been a great honour to serve as the exclusive expert contributors for Poland to the OneTrust DataGuidance Privacy Overview – Poland, one of the world&#8217;s leading professional legal [&#8230;]</p>
<p>Artykuł <a href="https://www.kg-legal.eu/info/kg-legal-news/a-major-milestone-for-kg-legals-data-ai-cybersecurity-practice-exclusive-poland-contribution-to-onetrust-dataguidance/">A Major Milestone for KG Legal&#8217;s Data, AI &amp; Cybersecurity Practice: Exclusive Poland Contribution to OneTrust DataGuidance</a> pochodzi z serwisu <a href="https://www.kg-legal.eu">KIELTYKA GLADKOWSKI LEGAL | CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p><strong><mark style="background-color:rgba(0, 0, 0, 0)" class="has-inline-color has-vivid-cyan-blue-color">Publication date: July 07, 2026</mark></strong></p>



<p>We are delighted to share an important milestone in the continued development of <strong>KG Legal&#8217;s Data, AI &amp; Cybersecurity Desk</strong>.</p>



<figure class="wp-block-image size-full"><img fetchpriority="high" decoding="async" width="1000" height="1000" src="https://www.kg-legal.eu/wp-content/uploads/2026/07/DataGuidance-Contributor-Badge.png" alt="" class="wp-image-8823" srcset="https://www.kg-legal.eu/wp-content/uploads/2026/07/DataGuidance-Contributor-Badge.png 1000w, https://www.kg-legal.eu/wp-content/uploads/2026/07/DataGuidance-Contributor-Badge-300x300.png 300w, https://www.kg-legal.eu/wp-content/uploads/2026/07/DataGuidance-Contributor-Badge-150x150.png 150w, https://www.kg-legal.eu/wp-content/uploads/2026/07/DataGuidance-Contributor-Badge-768x768.png 768w" sizes="(max-width: 1000px) 100vw, 1000px" /></figure>



<p>It has been a great honour to serve as the <strong>exclusive expert contributors for Poland</strong> to the <strong>OneTrust DataGuidance Privacy Overview – Poland</strong>, one of the world&#8217;s leading professional legal compliance resources relied upon by in-house counsel, privacy professionals, compliance officers, multinational organisations and technology companies operating across multiple jurisdictions.</p>



<span id="more-8822"></span>



<p>Preparing this contribution was a long-term project that required several months of intensive legal analysis, research and editorial work. Our objective was not simply to describe the application of the GDPR in Poland. Instead, we sought to create a practical and comprehensive guide reflecting the significant transformation of the Polish regulatory landscape that has taken place in recent years as a result of new European legislation and its implementation into Polish law.</p>



<p>The publication therefore extends far beyond a traditional overview of Polish data protection law. It examines the interaction between privacy, digital regulation, cybersecurity and artificial intelligence, providing readers with practical guidance on the most important legal developments affecting organisations operating in Poland.</p>



<p>Our contribution discusses, among other things:</p>



<ul class="wp-block-list">
<li>the practical application of the GDPR within the Polish legal system;</li>



<li>the powers and regulatory practice of the Polish supervisory authority for personal data protection;</li>



<li>employee monitoring and workplace privacy;</li>



<li>cookies, consent mechanisms and online tracking technologies;</li>



<li>electronic communications and direct marketing requirements;</li>



<li>international data transfers;</li>



<li>personal data breaches and notification obligations;</li>



<li>practical compliance with Polish privacy legislation;</li>



<li>cybersecurity-related regulatory developments;</li>



<li>the growing interaction between data protection and artificial intelligence governance.</li>
</ul>



<p>A particularly important aspect of this work was addressing the rapidly evolving legislative environment. During the last few years, Poland has experienced substantial regulatory changes resulting from the implementation of numerous European legal instruments and the entry into force of directly applicable EU regulations that significantly affect organisations processing personal data.</p>



<p>Accordingly, the publication takes into account the practical implications of the evolving European digital regulatory framework, including the interaction between the GDPR and newer legal instruments governing digital services, artificial intelligence, cybersecurity and data governance. The analysis also reflects the impact of the AI regulatory framework, developments concerning data governance and electronic communications, as well as the increasingly interconnected compliance obligations facing businesses operating in today&#8217;s digital economy.</p>



<p>Rather than presenting legislation in isolation, the publication adopts a practical, compliance-oriented perspective. It combines:</p>



<ul class="wp-block-list">
<li>the GDPR and Polish implementing legislation;</li>



<li>guidance issued by the European Data Protection Board (EDPB);</li>



<li>the jurisprudence of the Court of Justice of the European Union;</li>



<li>decisions and regulatory guidance published by the Polish Personal Data Protection Office (UODO);</li>



<li>recent Polish legislative developments and market practice.</li>
</ul>



<p>Our ambition was to create a resource that would assist both international and domestic organisations in navigating one of the fastest-changing areas of European regulation, where privacy law increasingly intersects with cybersecurity, AI governance, digital platforms, online communications and emerging technologies.</p>



<p>The contribution was prepared by <strong>Małgorzata Kiełtyka</strong> and <strong>Jakub Gładkowski</strong>, whose combined experience covers complex cross-border advisory work in data protection, artificial intelligence, life sciences, healthcare, technology law, cybersecurity, intellectual property and regulatory compliance.</p>



<p><a href="https://www.dataguidance.com/experts-directory/Jakub_G%C5%82adkowski" target="_blank" rel="noreferrer noopener">https://www.dataguidance.com/experts-directory/Jakub_G%C5%82adkowski</a></p>



<p><a href="https://www.dataguidance.com/experts-directory/Malgorzata_Kieltyka">https://www.dataguidance.com/experts-directory/Malgorzata_Kieltyka</a></p>



<p>For many years, Małgorzata Kiełtyka has advised international companies on GDPR compliance, healthcare regulation, AI governance, technology transactions and cross-border regulatory matters. Her practice combines strategic legal advice with practical implementation of compliance frameworks for multinational businesses operating in highly regulated sectors.</p>



<p>Jakub Gładkowski focuses on data protection, digital regulation, cybersecurity, intellectual property, IT law and emerging technologies. His practice includes advising innovative businesses on regulatory compliance, digital transformation projects and the implementation of European technology legislation affecting both public and private sector organisations.</p>



<p>Being entrusted with preparing Poland&#8217;s national contribution to OneTrust DataGuidance represents an important recognition of our team&#8217;s expertise and international standing. We are particularly proud that this publication reflects not only our experience in privacy law, but also our broader interdisciplinary approach, integrating data protection with AI regulation, cybersecurity, digital compliance and technology law.</p>



<p>We sincerely thank the editorial team at <strong>OneTrust DataGuidance</strong> for their confidence in our expertise and for the opportunity to contribute to a publication that supports legal and compliance professionals around the world.</p>



<p>For KG Legal, this publication marks another significant milestone in the continued growth of our <strong>Data, AI &amp; Cybersecurity Desk</strong> and reinforces our commitment to delivering practical, business-oriented legal advice at the intersection of privacy, technology and innovation.</p>
<p> </p>
<p>Artykuł <a href="https://www.kg-legal.eu/info/kg-legal-news/a-major-milestone-for-kg-legals-data-ai-cybersecurity-practice-exclusive-poland-contribution-to-onetrust-dataguidance/">A Major Milestone for KG Legal&#8217;s Data, AI &amp; Cybersecurity Practice: Exclusive Poland Contribution to OneTrust DataGuidance</a> pochodzi z serwisu <a href="https://www.kg-legal.eu">KIELTYKA GLADKOWSKI LEGAL | CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.kg-legal.eu/info/kg-legal-news/a-major-milestone-for-kg-legals-data-ai-cybersecurity-practice-exclusive-poland-contribution-to-onetrust-dataguidance/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Dietary Supplements Under Tightened Scrutiny: How the 2026 Reform Could Reshape the Polish Market</title>
		<link>https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/dietary-supplements-under-tightened-scrutiny-how-the-2026-reform-could-reshape-the-polish-market/</link>
					<comments>https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/dietary-supplements-under-tightened-scrutiny-how-the-2026-reform-could-reshape-the-polish-market/#respond</comments>
		
		<dc:creator><![CDATA[jakub]]></dc:creator>
		<pubDate>Tue, 07 Jul 2026 18:09:37 +0000</pubDate>
				<category><![CDATA[PHARMACEUTICAL, HEALTHCARE & LIFE SCIENCES LAW]]></category>
		<category><![CDATA[Administrative Law]]></category>
		<category><![CDATA[Advertising Law]]></category>
		<category><![CDATA[Compliance Risk]]></category>
		<category><![CDATA[CONSUMER PROTECTION]]></category>
		<category><![CDATA[Corporate Compliance]]></category>
		<category><![CDATA[Cross Border Business]]></category>
		<category><![CDATA[Digital Compliance]]></category>
		<category><![CDATA[Doing business in Poland]]></category>
		<category><![CDATA[EU Food Regulation]]></category>
		<category><![CDATA[eu regulation]]></category>
		<category><![CDATA[Food Law]]></category>
		<category><![CDATA[Food Safety]]></category>
		<category><![CDATA[GIS Poland]]></category>
		<category><![CDATA[Healthcare Law]]></category>
		<category><![CDATA[International Law Firms]]></category>
		<category><![CDATA[Invest in Poland]]></category>
		<category><![CDATA[Legal Services Poland]]></category>
		<category><![CDATA[Life Sciences Law]]></category>
		<category><![CDATA[Life Sciences Regulation]]></category>
		<category><![CDATA[Marketing Compliance]]></category>
		<category><![CDATA[Pharmaceutical Law]]></category>
		<category><![CDATA[Poland Law]]></category>
		<category><![CDATA[Polish law]]></category>
		<category><![CDATA[Regulatory Compliance]]></category>
		<category><![CDATA[Sanitary Regulation]]></category>
		<guid isPermaLink="false">https://www.kg-legal.eu/?p=8807</guid>

					<description><![CDATA[<p>Publication date: July 07, 2026 The Polish dietary supplements market is facing the most significant regulatory overhaul in years. The draft amendment to the Act on Food and Nutrition Safety and the Act on the State Sanitary Inspectorate introduces a series of far-reaching changes that will substantially alter the way supplements are notified, monitored, advertised, [&#8230;]</p>
<p>Artykuł <a href="https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/dietary-supplements-under-tightened-scrutiny-how-the-2026-reform-could-reshape-the-polish-market/">Dietary Supplements Under Tightened Scrutiny: How the 2026 Reform Could Reshape the Polish Market</a> pochodzi z serwisu <a href="https://www.kg-legal.eu">KIELTYKA GLADKOWSKI LEGAL | CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p><strong><mark style="background-color:rgba(0, 0, 0, 0)" class="has-inline-color has-vivid-cyan-blue-color">Publication date: July 07, 2026</mark></strong></p>



<p>The Polish dietary supplements market is facing the most significant regulatory overhaul in years. The draft amendment to the Act on Food and Nutrition Safety and the Act on the State Sanitary Inspectorate introduces a series of far-reaching changes that will substantially alter the way supplements are notified, monitored, advertised, and supervised in Poland. While the reform does not formally introduce a pre-market authorization system, it undeniably strengthens the position of regulatory authorities and increases the compliance burden imposed on businesses operating in the sector.</p>



<span id="more-8807"></span>



<p id="ember2883">The amendment, expected to enter into force six months after publication, reflects both domestic concerns regarding the rapid expansion of the supplements market and the broader European trend toward stricter food safety oversight. For manufacturers, importers, distributors, and marketing agencies, the proposed changes may require a complete reassessment of internal procedures, legal risk management, and commercial strategy.</p>



<p id="ember2884">The reform arrives at a time when the Polish dietary supplements market continues to expand at an exceptional pace. Poland has become one of the largest supplement consumers in the European Union, both in terms of total market value and per capita spending. According to market estimates, the sector exceeded PLN 7 billion in value in 2024 and is expected to continue growing steadily over the coming years. The scale of the market alone has become a challenge for regulators. Between 2017 and 2020, more than 62,000 supplement notifications were submitted to the Chief Sanitary Inspectorate (GIS), while the number of products listed in official registers exceeded 29,000.</p>



<p id="ember2885">At the same time, authorities increasingly pointed to systemic weaknesses in the existing framework. Under the current rules, a business may place a dietary supplement on the market immediately after submitting a notification to GIS, even if doubts exist regarding the product’s composition or classification. The authorities may initiate explanatory proceedings, but the product can still remain commercially available during the investigation. In practice, this system has often been criticized for providing insufficient preventive control and allowing potentially problematic products to circulate before any meaningful assessment takes place.</p>



<p id="ember2886">Another major concern involved the widespread use of aggressive advertising strategies. For years, the dietary supplements industry has been accused of blurring the line between supplements and medicinal products. Many advertisements indirectly suggested therapeutic effects or implied that supplements could substitute proper medical treatment or balanced nutrition. Regulators and pharmaceutical companies repeatedly argued that existing penalties were too low to deter large market participants from engaging in questionable promotional practices.</p>



<p id="ember2887">The lack of a centralized digital supervision system also contributed to inefficiencies. The notification process relied partly on outdated administrative mechanisms, resulting in difficulties with document verification, inconsistent communication, and lengthy proceedings. The new amendment seeks to address these concerns through digitalization, stricter procedural obligations, and substantially higher financial sanctions.</p>



<p id="ember2888">One of the most visible changes introduced by the reform is the mandatory use of the e-Sanepid platform for all supplement notifications. Until now, notifications could be submitted either electronically or in paper form, and businesses had some flexibility regarding the form and timing of submission. Under the new rules, however, the process becomes fully digitized. Notifications will only be accepted through the e-Sanepid system and will require either a qualified electronic signature or a trusted electronic profile.</p>



<p id="ember2889">This change may appear largely technical at first glance, but in reality it significantly increases the formalization of the entire notification process. For large companies with developed compliance departments, adapting to electronic communication systems is unlikely to create serious difficulties. Smaller businesses, however, may face operational and financial challenges connected with digital authentication tools, procedural monitoring, and document management requirements.</p>



<p id="ember2890">The amendment also changes the moment at which the notification obligation arises. Previously, the law referred both to products already introduced to the market and those merely intended for future introduction. The new wording removes the reference to “intended introduction,” meaning that the obligation will arise only once the product is actually being placed on the market. Although this clarification simplifies the legal interpretation of the obligation, it also narrows the flexibility businesses previously enjoyed when planning product launches.</p>



<p id="ember2891">Perhaps the most consequential aspect of the reform concerns explanatory proceedings and scientific opinions. Under the current framework, businesses could effectively delay proceedings indefinitely by postponing the submission of required scientific documentation. While the law imposed certain deadlines on the authorities themselves, it did not establish sufficiently strict obligations for the notifying entity. This created situations where proceedings remained unresolved for years, significantly limiting the effectiveness of supervision.</p>



<p id="ember2892">The amendment introduces a much stricter procedural regime. Once GIS requests a scientific opinion regarding a product’s classification or compliance, the business will have only 14 days to submit an application to a scientific institution or to the President of the Office for Registration of Medicinal Products. Furthermore, the scientific opinion itself must generally be issued within six months, with an absolute maximum period of twelve months in exceptional cases.</p>



<p id="ember2893">The most significant innovation is the introduction of a legal presumption against the entrepreneur. If the entity fails to submit the application for an opinion within the required 14-day period, the law will automatically presume that the proposed classification of the product is incorrect and that the product does not meet the requirements applicable to its category. In practical terms, procedural inactivity itself may lead to negative legal consequences.</p>



<p id="ember2894">This fundamentally changes the balance between businesses and regulatory authorities. Previously, delaying the process often worked in favor of companies by allowing products to remain on the market while proceedings continued. Under the new rules, inaction may immediately weaken the entrepreneur’s legal position. Businesses will therefore need to implement much stricter internal monitoring systems to ensure compliance with procedural deadlines.</p>



<p id="ember2895">The amendment additionally prohibits businesses from circumventing the procedure by repeatedly submitting notifications for identical products. Once proceedings are initiated, companies will no longer be able to submit another notification concerning a product with the same qualitative and quantitative composition. Similarly, withdrawing a notification will not allow the entrepreneur to restart the process with the same formula at a later stage. These restrictions are intended to eliminate procedural abuse and prevent companies from avoiding regulatory scrutiny through repeated filings.</p>



<p id="ember2896">Another major reform concerns transparency and the expansion of the public product register maintained within the SEPIS system. The current register already contains certain information regarding notified products, but the scope of publicly available data remains relatively limited. The new system significantly broadens the amount of information accessible to consumers and competitors alike.</p>



<p id="ember2897">Under the amendment, the register will include the product name, form of the product, qualitative composition, information regarding active substances, details concerning explanatory proceedings, and information about prohibited ingredients. Although quantitative composition data and certain identifying information regarding the reporting entity will remain confidential, the reform nevertheless represents a substantial increase in market transparency.</p>



<p id="ember2898">From the consumer protection perspective, this may be viewed as a positive development. Consumers will gain easier access to information about supplement composition and regulatory status, potentially allowing for more informed purchasing decisions. However, from the business perspective, the new transparency rules create considerable reputational risks. Information regarding ongoing explanatory proceedings may become publicly visible long before any final administrative decision is issued. As a result, companies may face reputational damage even in situations where no violation is ultimately confirmed.</p>



<p id="ember2899">The reform also updates the broader inspection framework to align Polish law with Regulation (EU) 2017/625 on official controls. Although the regulation has already been directly applicable across the European Union since 2019, several references in Polish legislation still pointed to repealed EU acts. The amendment therefore modernizes the legal terminology and adapts national provisions to the currently binding European framework.</p>



<p id="ember2900">Importantly, however, the changes do not significantly expand the substantive powers of sanitary authorities. The amendment primarily introduces terminological adjustments, extending references from “official food controls” to “official controls and other official activities.” Sanitary authorities will continue to possess extensive powers during inspections, including access to facilities, examination of production processes and documentation, and collection of samples for laboratory testing.</p>



<p id="ember2901">The reform does, however, expand the situations in which businesses must bear the costs of inspections and administrative activities. In addition to existing obligations related to violations, follow-up inspections, and border sanitary controls, businesses will now also be required to cover costs associated with official activities performed at their own request, such as the issuance of certain documents. While this change may appear relatively modest compared to other parts of the reform, it nevertheless contributes to the overall increase in operational costs for market participants.</p>



<p id="ember2902">One of the most controversial elements of the amendment concerns advertising and marketing practices. The reform significantly broadens the scope of administrative liability related to the promotion and presentation of dietary supplements. Previously, penalties focused primarily on incorrect product labeling. Under the new rules, liability will explicitly extend to advertising, online promotion, social media activities, and the overall presentation of products.</p>



<p id="ember2903">Most importantly, the amendment introduces severe sanctions for advertising or presenting a supplement before notifying GIS. This is likely to have a major impact on digital marketing strategies commonly used in the supplements industry. Influencer campaigns, online pre-launch promotions, teaser advertisements, and social media product announcements may all potentially fall within the scope of the new sanctions if conducted before formal notification.</p>



<p id="ember2904">The amendment also reinforces existing prohibitions against suggesting that a balanced diet cannot provide sufficient nutrients or implying medicinal properties of supplements. Although these prohibitions already existed under current law, the reform significantly strengthens enforcement mechanisms by attaching much higher financial penalties to violations.</p>



<p id="ember2905">Indeed, the increase in administrative penalties represents one of the most dramatic aspects of the reform. Under the current framework, the maximum administrative fine generally amounts to thirty times the average monthly salary. The amendment raises this threshold to one hundred times the average salary, increasing potential penalties by more than 330 percent.</p>



<p id="ember2906">Based on current economic indicators, maximum fines could exceed PLN 800,000. Such amounts are clearly intended to function as genuinely deterrent sanctions rather than symbolic administrative measures. For large corporations with extensive marketing operations, these penalties may significantly alter risk calculations related to aggressive advertising or borderline compliance practices.</p>



<p id="ember2907">For businesses operating in the supplements sector, the cumulative impact of these changes may be substantial. Compliance costs are likely to increase considerably. Companies may need to invest in legal advisory services, digital infrastructure, scientific assessments, employee training, and enhanced compliance monitoring systems. Marketing departments in particular will face increased scrutiny and will need to carefully verify advertising content before publication.</p>



<p id="ember2908">The reform may also contribute to market consolidation. Large, well-established companies are generally better positioned to absorb increased compliance costs and adapt to stricter regulatory requirements. Smaller businesses, startups, and niche supplement brands may struggle with the financial and administrative burden created by the new framework. As a result, the amendment could unintentionally reduce market diversity and strengthen the competitive position of major industry players.</p>



<p id="ember2909">From the perspective of public authorities, the reform aims to improve the efficiency and credibility of food safety supervision. Digitalization through e-Sanepid and SEPIS is expected to accelerate administrative processes, improve data analysis capabilities, and strengthen market oversight. The introduction of strict procedural deadlines should also reduce the risk of excessively lengthy proceedings and administrative disputes.</p>



<p id="ember2910">At the same time, the implementation of these systems will require significant investments in technological infrastructure and administrative capacity. The effectiveness of the reform will therefore depend not only on the wording of the legislation itself, but also on the practical ability of GIS and related institutions to manage the new digital environment efficiently.</p>



<p id="ember2911">Ultimately, the amendment does not formally transform dietary supplements into products requiring prior authorization before market entry. Businesses will still be able to introduce supplements through a notification-based system rather than a licensing procedure. Nevertheless, the practical reality of operating in the sector is likely to change considerably.</p>



<p id="ember2912">The reform substantially increases the procedural obligations imposed on businesses, strengthens enforcement tools available to authorities, raises financial exposure connected with non-compliance, and introduces far greater transparency into the market. While these changes may improve consumer protection and market oversight, they also create new operational and reputational risks for entrepreneurs.</p>



<p id="ember2913">For companies active in the supplements industry, the coming months may therefore become a critical period of preparation. Businesses that fail to adapt quickly to the new regulatory environment may face not only financial penalties, but also significant disruptions to their commercial operations and marketing strategies.</p>
<p> </p>


<p>Artykuł <a href="https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/dietary-supplements-under-tightened-scrutiny-how-the-2026-reform-could-reshape-the-polish-market/">Dietary Supplements Under Tightened Scrutiny: How the 2026 Reform Could Reshape the Polish Market</a> pochodzi z serwisu <a href="https://www.kg-legal.eu">KIELTYKA GLADKOWSKI LEGAL | CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/dietary-supplements-under-tightened-scrutiny-how-the-2026-reform-could-reshape-the-polish-market/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
	</channel>
</rss>
